Sabra Health Care REIT (SBRA) 10-Q 8 May 19 2019 Q1 Quarterly report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION - shares	3 Months Ended
	Mar. 31, 2019	May 01, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Sabra Health Care REIT, Inc.
Entity Central Index Key	0001492298
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		179,501,043

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Assets
Real estate investments, net of accumulated depreciation of $425,962 and $402,338 as of March 31, 2019 and December 31, 2018, respectively	$ 5,437,354	$ 5,853,545
Loans receivable and other investments, net	109,214	113,722
Investment in unconsolidated joint venture	335,701	340,120
Cash and cash equivalents	22,873	50,230
Restricted cash	9,766	9,428
Assets held for sale, net	270,780	0
Lease intangible assets, net	119,667	131,097
Accounts receivable, prepaid expenses and other assets, net	149,790	167,161
Total assets	6,455,145	6,665,303
Liabilities
Secured debt, net	115,188	115,679
Revolving credit facility	620,000	624,000
Term loans, net	1,187,384	1,184,930
Senior unsecured notes, net	1,307,658	1,307,394
Accounts payable and accrued liabilities	94,809	94,827
Lease intangible liabilities, net	79,328	83,726
Total liabilities	3,404,367	3,410,556
Commitments and contingencies (Note 13)
Equity
Common stock, $.01 par value; 250,000,000 shares authorized, 178,419,599 and 178,306,528 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively	1,784	1,783
Additional paid-in capital	3,508,987	3,507,925
Cumulative distributions in excess of net income	(462,555)	(271,595)
Accumulated other comprehensive (loss) income	(1,747)	12,301
Total Sabra Health Care REIT, Inc. stockholders’ equity	3,046,469	3,250,414
Noncontrolling interests	4,309	4,333
Total equity	3,050,778	3,254,747
Total liabilities and equity	$ 6,455,145	$ 6,665,303

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Assets
Accumulated depreciation	$ 425,962	$ 402,338
Common stock
Par value (in dollars per share)	$ 0.01	$ 0.01
Shares authorized (in shares)	250,000,000	250,000,000
Shares issued (in shares)	178,419,599	178,306,528
Shares outstanding (in shares)	178,419,599	178,306,528

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF (LOSS) INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenues:
Rental and related revenues	$ 116,387	$ 144,255
Interest and other income	3,325	4,338
Resident fees and services	17,061	17,493
Total revenues	136,773	166,086
Expenses:
Depreciation and amortization	44,949	48,005
Interest	36,318	35,818
General and administrative	8,178	7,867
Merger and acquisition costs	6	330
Provision for doubtful accounts, straight-line rental income and loan losses	1,207	1,213
Impairment of real estate	103,134	532
Total expenses	211,121	105,889
Other (expense) income:
Other income	171	2,820
Net loss on sales of real estate	(1,520)	(472)
Total other (expense) income	(1,349)	2,348
(Loss) income before (loss) income from unconsolidated joint venture and income tax expense	(75,697)	62,545
(Loss) income from unconsolidated joint venture	(1,383)	446
Income tax expense	(612)	(510)
Net (loss) income	(77,692)	62,481
Net income attributable to noncontrolling interests	(12)	(10)
Net (loss) income attributable to Sabra Health Care REIT, Inc.	(77,704)	62,471
Preferred stock dividends	0	(2,561)
Net (loss) income attributable to common stockholders	$ (77,704)	$ 59,910
Net (loss) income attributable to common stockholders, per:
Basic common share (in dollars per share)	$ (0.44)	$ 0.34
Diluted common share (in dollars per share)	$ (0.44)	$ 0.34
Weighted-average number of common shares outstanding, basic (in shares)	178,385,984	178,294,605
Weighted-average number of common shares outstanding, diluted (in shares)	178,385,984	178,516,388
Triple-Net Portfolio
Expenses:
Operating expenses	$ 5,289	$ 0
Senior Housing - Managed
Expenses:
Operating expenses	$ 12,040	$ 12,124

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (77,692)	$ 62,481
Unrealized gain (loss), net of tax:
Foreign currency translation loss	(560)	(374)
Unrealized (loss) gain on cash flow hedges	(13,488)	9,898
Total other comprehensive (loss) income	(14,048)	9,524
Comprehensive (loss) income	(91,740)	72,005
Comprehensive income attributable to noncontrolling interests	(12)	(10)
Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc.	$ (91,752)	$ 71,995

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Thousands	Total	Total Stockholders’ Equity	Preferred Stock	Common Stock	Additional Paid-in Capital	Cumulative Distributions in Excess of Net Income	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2017			5,750,000	178,255,843
Beginning balance at Dec. 31, 2017	$ 3,437,249	$ 3,432,807	$ 58	$ 1,783	$ 3,636,913	$ (217,236)	$ 11,289	$ 4,442
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	62,481	62,471				62,471		10
Other comprehensive income (loss)	8,729	8,729					8,729
Distributions to noncontrolling interests	(37)							(37)
Amortization of stock-based compensation	1,398	1,398			1,398
Common stock issuance, net (in shares)				26,527
Common stock issuance, net	(202)	(202)			(202)
Preferred dividends	(2,561)	(2,561)				(2,561)
Common dividends	(80,491)	(80,491)				(80,491)
Ending balance (in shares) at Mar. 31, 2018			5,750,000	178,282,370
Ending balance at Mar. 31, 2018	3,426,566	3,422,151	$ 58	$ 1,783	3,638,109	(238,612)	20,813	4,415
Beginning balance (in shares) at Dec. 31, 2018			0	178,306,528
Beginning balance at Dec. 31, 2018	3,254,747	3,250,414	$ 0	$ 1,783	3,507,925	(271,595)	12,301	4,333
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	(77,692)	(77,704)				(77,704)		12
Other comprehensive income (loss)	(14,048)	(14,048)					(14,048)
Distributions to noncontrolling interests	(36)							(36)
Amortization of stock-based compensation	3,270	3,270			3,270
Common stock issuance, net (in shares)				113,071
Common stock issuance, net	(2,207)	(2,207)		$ 1	(2,208)
Common dividends	(80,754)	(80,754)				(80,754)
Ending balance (in shares) at Mar. 31, 2019			0	178,419,599
Ending balance at Mar. 31, 2019	$ 3,050,778	$ 3,046,469	$ 0	$ 1,784	$ 3,508,987	$ (462,555)	$ (1,747)	$ 4,309

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares	Feb. 05, 2019	Mar. 31, 2019	Mar. 31, 2018
Statement of Stockholders' Equity [Abstract]
Common dividends (in dollars per share)	$ 0.45	$ 0.45	$ 0.45

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net (loss) income	$ (77,692)	$ 62,481
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	44,949	48,005
Amortization of above and below market lease intangibles, net	4,304	(684)
Non-cash interest income adjustments	(562)	(570)
Non-cash interest expense	2,561	2,481
Stock-based compensation expense	2,775	1,135
Straight-line rental income adjustments	(5,468)	(11,563)
Provision for doubtful accounts, straight-line rental income and loan losses	1,207	1,213
Net loss on sales of real estate	1,520	472
Impairment of real estate	103,134	532
Loss (income) from unconsolidated joint venture	1,383	(446)
Distributions of earnings from unconsolidated joint venture	3,037	0
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other assets, net	(9,924)	(1,658)
Accounts payable and accrued liabilities	(17,265)	249
Net cash provided by operating activities	53,959	101,647
Cash flows from investing activities:
Acquisition of real estate	0	(172,001)
Origination and fundings of loans receivable	(2,776)	(13,232)
Origination and fundings of preferred equity investments	0	(928)
Additions to real estate	(5,072)	(11,539)
Repayments of loans receivable	5,251	28,805
Repayments of preferred equity investments	2,087	234
Investment in unconsolidated joint venture	0	(354,461)
Net proceeds from the sales of real estate	6,857	6,743
Net cash provided by (used in) investing activities	6,347	(516,379)
Cash flows from financing activities:
Net repayments of revolving credit facility	(4,000)	(30,000)
Principal payments on secured debt	(849)	(1,061)
Payments of deferred financing costs	(6)	(6)
Distributions to noncontrolling interests	(36)	(37)
Issuance of common stock, net	(2,323)	(499)
Dividends paid on common and preferred stock	(80,260)	(82,789)
Net cash used in financing activities	(87,474)	(114,392)
Net decrease in cash, cash equivalents and restricted cash	(27,168)	(529,124)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	149	(155)
Cash, cash equivalents and restricted cash, beginning of period	59,658	587,449
Cash, cash equivalents and restricted cash, end of period	32,639	58,170
Supplemental disclosure of cash flow information:
Interest paid	$ 42,195	$ 42,623

BUSINESS

BUSINESS	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS	BUSINESS Overview Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra’s separation from Sun. Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its United States (“U.S.”) federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants and operators throughout the U.S. and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and a wholly owned subsidiary of Sabra is currently the only limited partner, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in loans receivable; preferred equity investments; and an investment in an unconsolidated joint venture. On August 17, 2017, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) entered into by the Company, the Operating Partnership, PR Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Merger Sub”), Care Capital Properties, Inc., a Delaware corporation (“CCP”), and Care Capital Properties, L.P. (“CCPLP”), a Delaware limited partnership and wholly owned subsidiary of CCP, CCP merged with and into Merger Sub, with Merger Sub continuing as the surviving corporation (the “CCP Merger”), following which Merger Sub merged with and into the Company, with the Company continuing as the surviving entity (the “Subsequent Merger”), and, simultaneous with the Subsequent Merger, CCPLP merged with and into the Operating Partnership, with the Operating Partnership continuing as the surviving entity.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of March 31, 2019 and December 31, 2018 and for the three month periods ended March 31, 2019 and 2018 . All significant intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019 . For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC. GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary. The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of March 31, 2019 , the Company determined that it was the primary beneficiary of one VIE—a joint venture variable interest entity owning one skilled nursing/transitional care facility—and has consolidated the operations of this entity in the accompanying condensed consolidated financial statements. As of March 31, 2019 , the Company determined that the operations of this entity were not material to the Company’s results of operations, financial condition or cash flows. As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At March 31, 2019 , none of the Company’s investments in loans were accounted for as real estate joint ventures. As it relates to investments in joint ventures, the Company assesses any limited partners’ rights and their impact on the presumption of control of the limited partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the sole general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of March 31, 2019 , the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Investment in Unconsolidated Joint Venture The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company’s share of the investee’s earnings or losses is included in the Company’s condensed consolidated statements of income. The initial carrying value of the investment is based on the amount paid to purchase the joint venture interest. Differences between the Company’s cost basis and the basis reflected at the joint venture level are generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company’s share of earnings of the joint venture. The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its equity method investments may not be recoverable or realized. When indicators of potential impairment are identified, the Company evaluates its equity method investments for impairment based on a comparison of the fair value of the investment to its carrying value. The fair value is estimated based on discounted cash flows that include all estimated cash inflows and outflows over a specified holding period and any estimated debt premiums or discounts. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its equity method investment, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its equity method investment. On January 2, 2018, the Company completed its transaction with affiliates of Enlivant and TPG Real Estate, the real estate platform of TPG, and contributed $352.7 million , before closing costs, to acquire a 49% equity interest in an entity that owns 172 senior housing communities managed by Enlivant (the “Enlivant Joint Venture”). At closing, the Enlivant Joint Venture had outstanding indebtedness of $791.3 million and net working capital of $22.9 million . The joint venture agreement includes an option for the Company to acquire the remainder of the outstanding equity interests in the Enlivant Joint Venture by January 2, 2021 and grants the Company the right of first offer if the Company’s partner in the Enlivant Joint Venture desires to transfer its equity interest (which it may do commencing on January 2, 2020). Sabra also has the right to designate three directors on the seven member board of directors of the Enlivant Joint Venture and has other customary minority rights. As of March 31, 2019 , the book value of the Company’s investment in the Enlivant Joint Venture was $335.7 million . Net Investment in Direct Financing Lease As of March 31, 2019 , the Company had a $23.5 million net investment in one skilled nursing/transitional care facility leased to an operator under a direct financing lease, as the tenant is obligated to purchase the property at the end of the lease term. The net investment in direct financing lease is recorded in accounts receivable, prepaid expenses and other assets, net on the accompanying condensed consolidated balance sheets and represents the total undiscounted rental payments of $5.2 million , plus the estimated unguaranteed residual value of $24.7 million , less the unearned lease income of $6.4 million as of March 31, 2019 . Unearned lease income represents the excess of the minimum lease payments and residual value over the cost of the investment. Unearned lease income is deferred and amortized to income over the lease term to provide a constant yield when collectability of the lease payments is reasonably assured. Income from the Company’s net investment in direct financing lease was $0.6 million for the three months ended March 31, 2019 and is reflected in interest and other income on the accompanying condensed consolidated statements of income. Future minimum lease payments contractually due under the direct financing lease at March 31, 2019 , were as follows: $1.7 million for the remainder of 2019; $2.3 million for 2020; and $2.1 million for 2021. Recently Issued Accounting Standards Update Adopted In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases, as amended by subsequent ASUs (“Topic 842”). Topic 842 supersedes guidance related to accounting for leases and provides for the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. The objective of Topic 842 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a lease. Topic 842 does not fundamentally change lessor accounting; however, some changes have been made to lessor accounting to conform and align that guidance with the lessee guidance and other areas within GAAP. Topic 842 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company elected to adopt Topic 842 on January 1, 2019 using the modified retrospective transition method, which permits application of the new standard on the adoption date as opposed to the earliest comparative period presented in the financial statements. In addition, the Company elected to use the available practical expedient package, and therefore did not reassess classification of its existing leases. Additionally, the Company has elected a practical expedient not to separate lease and nonlease components (such as services rendered), which can only be applied to leasing arrangements for which (i) the timing and pattern of transfer are the same for the lease and nonlease components and (ii) the lease component, if accounted for separately, would be classified as an operating lease. Under this practical expedient, contracts that are predominantly lease-based would be accounted for under Topic 842, and contracts that are predominantly service-based would be accounted for under Topic 606, Revenue from Contracts with Customers. As a result of electing this practical expedient, the Company, beginning January 1, 2019, recognizes revenue from its leased skilled nursing/transitional care facilities, senior housing communities, and specialty hospitals and other facilities under Topic 842 and recognizes revenue from its Senior Housing - Managed communities under the Revenue ASUs (codified under Topic 606). Upon adoption of Topic 842, the Company recognized its operating leases for which it is the lessee, mainly its corporate office lease and ground leases, on its consolidated balance sheets, as a lease liability of $10.0 million , included in accounts payable and accrued liabilities on the condensed consolidated balance sheets, and a corresponding right-of-use asset, included in accounts receivable, prepaid expenses and other assets, net on the condensed consolidated balance sheets. As of March 31, 2019 , the balances of the lease liability and the corresponding right-of-use asset were $10.0 million and $9.8 million , respectively. The Company assesses the collectability of rental revenues on a lease-by-lease basis. Prior to the adoption of Topic 842, the Company recorded rental revenue and receivables to the extent those amounts were expected to be collected, irrespective of the Company’s determination of the collectability of substantially all rents over the life of a lease. Upon adoption of Topic 842, if at any time the Company cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received and all receivables associated with the lease will be written off irrespective of amounts expected to be collectible. Upon adoption of Topic 842 and as of the adoption date, the Company recorded a $32.5 million reduction in equity and accounts receivable due to the cumulative effect of this change. This reduction consisted of $17.5 million of straight-line rental income receivables and $15.0 million of cash rent receivables, although management believes the $15.0 million of cash rent receivables are collectible. Any recoveries of these amounts will be recorded in future periods upon receipt of payment. Under Topic 842, future write-offs of receivables and any recoveries of previously written-off receivables will be recorded as adjustments to rental revenue. Furthermore, Topic 842 requires lessors to exclude from variable payments lessor costs paid by lessees directly to third parties. In contrast, lessor costs that are paid by the lessor and reimbursed by the lessee are included in the measurement of variable lease revenue and the associated expense. As a result, the Company recognized $4.2 million of variable lease revenue and the associated expense during the three months ended March 31, 2019 . Issued but Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires that a financial asset (or a group of financial assets) measured at amortized cost basis be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The amendments in ASU 2016-13 are an improvement because they eliminate the probable initial recognition threshold under current GAAP and, instead, reflect an entity’s current estimate of all expected credit losses. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. In November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2018-19”), which amends ASU 2016-13 to clarify that receivables arising from operating leases are not within the scope of Subtopic 326-20, and instead, impairment of such receivables should be accounted for in accordance with Topic 842, Leases. ASU 2016-13 and ASU 2018-19 are effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted as of the fiscal years beginning after December 15, 2018. An entity will apply the amendments in these updates through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). ASU 2018-13 updates the fair value measurement disclosure requirements by (i) eliminating certain requirements, including disclosure of the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and the valuation processes for Level 3 fair value measurements, (ii) modifying certain requirements, including clarifying that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date and (iii) adding certain requirements, including disclosure of the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted for any eliminated or modified disclosures. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted.

RECENT REAL ESTATE ACQUISITIONS

RECENT REAL ESTATE ACQUISITIONS	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
RECENT REAL ESTATE ACQUISITIONS	RECENT REAL ESTATE ACQUISITIONS No acquisitions were completed during the three months ended March 31, 2019 . During the three months ended March 31, 2018 , the Company acquired 11 Senior Housing - Managed communities, two skilled nursing/transitional care facilities and one senior housing community. Allocation of the consideration was based on certain valuations and analyses and is as follows (in thousands): Three Months Ended March 31, 2018 Land $ 20,552 Building and improvements 150,523 Tenant origination and absorption costs intangible assets 722 Tenant relationship intangible assets 209 Total consideration $ 172,006 For the acquisitions completed during the three months ended March 31, 2018 , the tenant origination and absorption costs intangible assets and tenant relationship intangible assets had weighted-average amortization periods as of the respective dates of acquisition of 13 years and 23 years , respectively. For the three months ended March 31, 2018 , the Company recognized $9.7 million of total revenues and $0.9 million of net income attributable to common stockholders from the facilities acquired during the three months ended March 31, 2018 .

REAL ESTATE PROPERTIES HELD FOR

REAL ESTATE PROPERTIES HELD FOR INVESTMENT	3 Months Ended
	Mar. 31, 2019
Real Estate Investments, Net [Abstract]
REAL ESTATE PROPERTIES HELD FOR INVESTMENT	REAL ESTATE PROPERTIES HELD FOR INVESTMENT The Company’s real estate properties held for investment consisted of the following (dollars in thousands): As of March 31, 2019 Property Type Number of Properties Number of Beds/Units Total Real Estate at Cost Accumulated Depreciation Total Real Estate Investments, Net Skilled Nursing/Transitional Care 304 34,049 $ 3,716,115 $ (234,633 ) $ 3,481,482 Senior Housing - Leased 88 7,147 1,220,158 (133,570 ) 1,086,588 Senior Housing - Managed 23 1,603 305,173 (22,037 ) 283,136 Specialty Hospitals and Other 22 1,085 621,236 (35,394 ) 585,842 437 43,884 5,862,682 (425,634 ) 5,437,048 Corporate Level 634 (328 ) 306 $ 5,863,316 $ (425,962 ) $ 5,437,354 As of December 31, 2018 Property Type Number of Properties Number of Beds/Units Total Real Estate at Cost Accumulated Depreciation Total Real Estate Investments, Net Skilled Nursing/Transitional Care 335 37,628 $ 4,094,484 $ (224,942 ) $ 3,869,542 Senior Housing - Leased 90 7,332 1,237,790 (125,902 ) 1,111,888 Senior Housing - Managed 23 1,603 301,739 (19,537 ) 282,202 Specialty Hospitals and Other 22 1,085 621,236 (31,640 ) 589,596 470 47,648 6,255,249 (402,021 ) 5,853,228 Corporate Level 634 (317 ) 317 $ 6,255,883 $ (402,338 ) $ 5,853,545 March 31, 2019 December 31, 2018 Building and improvements $ 5,044,382 $ 5,388,102 Furniture and equipment 221,123 237,145 Land improvements 1,317 1,254 Land 596,494 629,382 5,863,316 6,255,883 Accumulated depreciation (425,962 ) (402,338 ) $ 5,437,354 $ 5,853,545 Operating Leases As of March 31, 2019 , the substantial majority of the Company’s real estate properties (excluding 23 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 15 years. As of March 31, 2019 , the leases had a weighted-average remaining term of nine years. The leases generally include provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. The Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets and totaled $12.6 million and $12.4 million as of March 31, 2019 and December 31, 2018 , respectively, and letters of credit deposited with the Company totaled approximately $95 million and $98 million as of March 31, 2019 and December 31, 2018 , respectively. In addition, the Company’s tenants have deposited with the Company $14.2 million and $17.5 million as of March 31, 2019 and December 31, 2018 , respectively, for future real estate taxes, insurance expenditures and tenant improvements related to the Company’s properties and their operations. Subsequent to the notices of default and lease termination issued by the Company to Senior Care Centers during the third quarter of 2018, on December 5, 2018, the Company entered into a purchase and sale agreement (as amended in January 2019) to sell 26 skilled nursing/transitional care facilities and two senior housing communities operated by Senior Care Centers for an aggregate sales price of $282.5 million . In addition, on February 15, 2019, the Company entered into a settlement agreement with Senior Care Centers which, in accordance with the order entered by the bankruptcy court in March 2019, provides for the discharge by the Company of its claims against Senior Care Centers in exchange for $9.5 million of settlement payments, a portion of which would be applied to pay post-petition rent. The Company recorded such post-petition rent totaling $5.7 million during the three months ended March 31, 2019 and expects to record an additional $0.5 million of post-petition rent during the second quarter of 2019. On April 1, 2019, the Company completed the sale of the 28 facilities and received gross sales proceeds of $282.5 million as well as $5.0 million of the settlement payments (with the remaining $4.5 million of settlement payments payable on or before July 1, 2019). In connection with the sale, the Company entered into an agreement to indemnify the buyer from certain costs, expenses and liabilities related to the historical operations of the facilities by Senior Care Centers. Of the 10 remaining facilities operated by Senior Care Centers, the Company expects to re-tenant seven facilities to a current operator in the Sabra portfolio and to sell three facilities. During the three months ended March 31, 2019, the Company recorded an impairment charge of $92.2 million related to the Senior Care Centers facilities, which includes $10.2 million related to the Company’s estimated contractual indemnification obligations. On December 19, 2018, the Company entered into a letter of intent to terminate its triple-net master lease with Holiday Retirement (“Holiday”) with respect to all 21 senior housing communities subject to the master lease (the “Holiday Communities”) and concurrently enter into management agreements pursuant to which Holiday would manage the Holiday Communities. On April 1, 2019, the Company completed the conversion of the Holiday Communities to its Senior Housing - Managed portfolio. In exchange for terminating the Holiday master lease, the Company received $57.2 million of total cash consideration. The Company monitors the creditworthiness of its tenants by reviewing credit ratings (if available) and evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants’ financial performance, including the evaluation of any parent guarantees (or the guarantees of other related parties) of tenant lease obligations. As formal credit ratings may not be available for most of the Company’s tenants, the primary basis for the Company’s evaluation of the credit quality of its tenants (and more specifically the tenant’s ability to pay their rent obligations to the Company) is the tenant’s lease coverage ratio or the parent’s fixed charge coverage ratio for those entities with a parent guarantee. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent (“EBITDAR”) to rent and earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the lease level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry’s operational and financial environment (including the impact of government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify potential areas of concern relative to its tenants’ credit quality and ultimately the tenant’s ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company. For the three months ended March 31, 2019 , no tenant relationship represented 10% or more of the Company’s total revenues. The future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows (in thousands): As of March 31, 2019 April 1 through December 31, 2019 $ 351,250 2020 456,660 2021 452,218 2022 454,086 2023 437,112 Thereafter 2,440,245 $ 4,591,571 As of December 31, 2018 2019 $ 465,766 2020 456,207 2021 452,346 2022 454,216 2023 437,277 Thereafter 2,407,064 $ 4,672,876 Senior Housing - Managed Communities The Company’s Senior Housing - Managed communities offer residents certain ancillary services that are not contemplated in the lease with each resident (i.e., housekeeping, laundry, guest meals, etc.). These services are provided and paid for in addition to the standard services included in each resident lease (i.e., room and board, standard meals, etc.). The Company bills residents for ancillary services one month in arrears and recognizes revenue as the services are provided, as the Company has no continuing performance obligation related to those services. Resident fees and services includes $0.1 million of ancillary service revenue for each of the three months ended March 31, 2019 and 2018 .

IMPAIRMENT OF REAL ESTATE, ASSE

IMPAIRMENT OF REAL ESTATE, ASSETS HELD FOR SALE AND DISPOSITIONS	3 Months Ended
	Mar. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
IMPAIRMENT OF REAL ESTATE, ASSETS HELD FOR SALE AND DISPOSITIONS	IMPAIRMENT OF REAL ESTATE, ASSETS HELD FOR SALE AND DISPOSITIONS 2019 Impairment of Real Estate During the three months ended March 31, 2019 , the Company recognized a $103.1 million real estate impairment, of which amount $92.2 million related to the 28 Senior Care Centers facilities sold on April 1, 2019 and the three Senior Care Centers facilities that the Company expects to sell, and the remaining $10.9 million related to four additional skilled nursing/transitional care facilities. Assets Held for Sale As of March 31, 2019 , the Company determined that 28 skilled nursing/transitional care facilities and two senior housing communities, with an aggregate net book value of $270.8 million , met the criteria to be classified as assets held for sale. Subsequent to March 31, 2019 , the Company completed the sale of 29 of the facilities for an aggregate gross sales price of $282.6 million . Dispositions During the three months ended March 31, 2019 , the Company completed the sale of three skilled nursing/transitional care facilities for aggregate consideration, net of closing costs, of $6.9 million . The net carrying value of the assets and liabilities of these facilities was $8.4 million , which resulted in an aggregate $1.5 million net loss on sale. Excluding the net loss on sale, the Company recognized $0.5 million and $17,000 of net income during the three months ended March 31, 2019 and 2018 , respectively, from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations. 2018 Impairment of Real Estate During the three months ended March 31, 2018 , the Company recognized a $0.5 million real estate impairment related to one senior housing community sold during the second quarter of 2018. Dispositions During the three months ended March 31, 2018 , the Company completed the sale of one skilled nursing/transitional care facility for consideration, net of closing costs, of $6.8 million . The net carrying value of the assets and liabilities of this facility was $7.2 million , which resulted in a $0.4 million net loss on sale. The Company also recognized an additional $0.1 million of selling expenses for sales completed in 2017. Excluding the net loss on sale, the Company recognized $0.1 million of net income during the three months ended March 31, 2018 from this facility. The sale of this facility does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to this facility have remained in continuing operations.

LOANS RECEIVABLE AND OTHER INVE

LOANS RECEIVABLE AND OTHER INVESTMENTS	3 Months Ended
	Mar. 31, 2019
Receivables [Abstract]
LOANS RECEIVABLE AND OTHER INVESTMENTS	LOANS RECEIVABLE AND OTHER INVESTMENTS As of March 31, 2019 and December 31, 2018 , the Company’s loans receivable and other investments consisted of the following (dollars in thousands): March 31, 2019 Investment Quantity as of March 31, 2019 Property Type Principal Balance as of March 31, 2019 (1) Book Value as of March 31, 2019 Book Value as of Weighted Average Contractual Interest Rate / Rate of Return Weighted Average Annualized Effective Interest Rate / Rate of Return Maturity Date as of March 31, 2019 Loans Receivable: Mortgage 1 Specialty Hospital $ 19,000 $ 19,000 $ 18,577 10.0 % 10.0 % 01/31/27 Construction 2 Senior Housing 4,887 4,945 4,629 8.0 % 7.7 % 04/30/21- 09/30/22 Mezzanine — Skilled Nursing — — 2,188 N/A N/A N/A Other 17 Multiple 47,633 43,611 45,324 7.1 % 7.7 % 02/28/19- 08/31/28 20 71,520 67,556 70,718 7.9 % 8.4 % Loan loss reserve — (1,767 ) (1,258 ) $ 71,520 $ 65,789 $ 69,460 Other Investments: Preferred Equity 9 Skilled Nursing / Senior Housing 43,014 43,425 44,262 12.0 % 12.0 % N/A Total 29 $ 114,534 $ 109,214 $ 113,722 9.4 % 9.8 % (1) Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees. As of March 31, 2019 and December 31, 2018 , the Company had six and seven loans receivable investments, respectively, with an aggregate principal balance of $3.4 million and $27.7 million , respectively, that were considered to have deteriorated credit quality. As of March 31, 2019 and December 31, 2018 , the book value of the outstanding loans with deteriorated credit quality was $1.8 million and $4.2 million , respectively. During the three months ended March 31, 2019 , one loan with deteriorated credit quality was repaid. The following table presents changes in the accretable yield for the three months ended March 31, 2019 and 2018 (in thousands): Three Months Ended March 31, 2019 2018 Accretable yield, beginning of period $ 449 $ 2,483 Accretion recognized in earnings (218 ) (599 ) Reduction due to payoff (33 ) — Accretable yield, end of period $ 198 $ 1,884 During the three months ended March 31, 2019 , the Company recorded a $1.2 million provision for specific loan losses and recorded a $27,000 reduction to its provision for portfolio-based loan losses. As of March 31, 2019 , the Company had a $1.2 million specific loan loss reserve and a $0.5 million portfolio-based loan loss reserve. As of March 31, 2019 , the Company considered one loan receivable investment to be impaired, which had a principal balance of $4.3 million as of each of March 31, 2019 and December 31, 2018 . As of March 31, 2019 , three loans receivable investments with an aggregate book value of $4.3 million were on nonaccrual status. As of March 31, 2019 , the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status. As of December 31, 2018 , the Company had a $0.7 million specific loan loss reserve and a $0.6 million portfolio-based loan loss reserve. As of December 31, 2018 , the Company considered one loan receivable investment with a principal balance of $1.3 million to be impaired, and two loans receivable investments with an aggregate book value of $1.3 million were on nonaccrual status. Additionally, as of December 31, 2018 , the Company recognized interest income related to one loan receivable investment, with a book value of $4.3 million , that was more than 90 days past due. As of December 31, 2018 , the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status. During the three months ended March 31, 2018 , the Company recorded no provision for specific loan losses and increased its portfolio-based loan loss reserve by $0.1 million .

DEBT

DEBT	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
DEBT	DEBT Secured Indebtedness The Company’s secured debt consists of the following (dollars in thousands): Interest Rate Type Principal Balance as of (1) Principal Balance as of (1) Weighted Average (2) Maturity Date Fixed Rate $ 116,954 $ 117,464 3.66 % December 2021 - (1) Principal balance does not include deferred financing costs, net of $ 1.8 million as of each of March 31, 2019 and December 31, 2018 . (2) Weighted average effective interest rate includes private mortgage insurance. Senior Unsecured Notes The Company’s senior unsecured notes consist of the following (dollars in thousands): Principal Balance as of Title Maturity Date March 31, 2019 (1) December 31, 2018 (1) 5.5% senior unsecured notes due 2021 (“2021 Notes”) February 1, 2021 $ 500,000 $ 500,000 5.375% senior unsecured notes due 2023 (“2023 Notes”) June 1, 2023 200,000 200,000 5.125% senior unsecured notes due 2026 (“2026 Notes”) August 15, 2026 500,000 500,000 5.38% senior unsecured notes due 2027 (“2027 Notes”) May 17, 2027 100,000 100,000 $ 1,300,000 $ 1,300,000 (1) Principal balance does not include premium, net of $14.1 million and deferred financing costs, net of $6.5 million as of March 31, 2019 and does not include premium, net of $14.5 million and deferred financing costs, net of $7.1 million as of December 31, 2018 . The 2021 Notes and the 2023 Notes were issued by the Operating Partnership and Sabra Capital Corporation, wholly owned subsidiaries of the Company (the “Issuers”). The 2021 Notes accrue interest at a rate of 5.5% per annum payable semiannually on February 1 and August 1 of each year, and the 2023 Notes accrue interest at a rate of 5.375% per annum payable semiannually on June 1 and December 1 of each year. The 2026 Notes and the 2027 Notes were assumed as a result of the CCP Merger and accrue interest at a rate of 5.125% and 5.38% , respectively, per annum. Interest is payable semiannually on February 15 and August 15 of each year for the 2026 Notes and on May 17 and November 17 of each year for the 2027 Notes. The obligations under the 2021 Notes, 2023 Notes and 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and certain subsidiaries of Sabra; provided, however, that such guarantees are subject to release under certain customary circumstances. The obligations under the 2026 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances. See Note 12, “Summarized Condensed Consolidating Information” for additional information concerning the circumstances pursuant to which the guarantors will be automatically and unconditionally released from their obligations under the guarantees. The indentures and agreements (the “Senior Notes Indentures”) governing the 2021 Notes, 2023 Notes, 2026 Notes and 2027 Notes (collectively, the “Senior Notes”) include customary events of default and require the Company to comply with specified restrictive covenants. As of March 31, 2019 , the Company was in compliance with all applicable financial covenants under the Senior Notes Indentures. Credit Facility Effective on August 17, 2017, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fourth amended and restated unsecured credit facility (the “Credit Facility”). The Credit Facility includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), $1.1 billion in U.S. dollar term loans and a CAD $125.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $175.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Facility also contains an accordion feature that can increase the total available borrowings to $2.5 billion , subject to terms and conditions. The Revolving Credit Facility has a maturity date of August 17, 2021, and includes two six -month extension options. $200.0 million of the U.S. dollar Term Loans has a maturity date of August 17, 2020, and the other Term Loans have a maturity date of August 17, 2022. As of March 31, 2019 , there was $620.0 million outstanding under the Revolving Credit Facility and $380.0 million available for borrowing. Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to an applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5% , (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Base Rate”). On August 17, 2017, Sabra’s ratings met the Investment Grade Ratings Criteria (as defined in the credit agreement), and Sabra elected to use the ratings-based applicable interest margin for borrowings which will vary based on the Debt Ratings, as defined in the credit agreement, and will range from 0.875% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Base Rate. As of March 31, 2019 , the interest rate on the Revolving Credit Facility was 3.74% . In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder. The U.S. dollar Term Loans bear interest on the outstanding principal amount at a rate equal to an applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the credit agreement, and will range from 0.90% to 1.90% per annum for LIBOR based borrowings and 0.00% to 0.90% per annum for borrowings at the Base Rate. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal to the Canadian Dollar Offered Rate (“CDOR”) plus an interest margin that will range from 0.90% to 1.90% depending on the Debt Ratings. On June 10, 2015, the Company entered into an interest rate swap agreement to fix the CDOR portion of the interest rate for CAD $90.0 million of its Canadian dollar Term Loan at 1.59% . In addition, CAD $90.0 million of the Canadian dollar Term Loan was designated as a net investment hedge. On August 10, 2016, the Company entered into two interest rate swap agreements to fix the LIBOR portion of the interest rate for $245.0 million of its U.S. dollar Term Loans at 0.90% and one interest rate swap agreement to fix the CDOR portion on CAD $35.0 million of its Canadian dollar Term Loan at 0.93% . See Note 8, “Derivative and Hedging Instruments” for further information. As a result of the CCP Merger, the Company assumed eight interest rate swap agreements that fix the LIBOR portion of the interest rate for $600 million of the Company’s U.S. dollar Term Loans at a weighted average rate of 1.31% . See Note 8, “Derivative and Hedging Instruments” for further information. The obligations of the Borrowers under the Credit Facility are guaranteed by Sabra and certain subsidiaries of Sabra. The Credit Facility contains customary covenants that include restrictions or limitations on the ability to make acquisitions and other investments, pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Facility also requires Sabra, through the Operating Partnership, to comply with specified financial covenants, which include a maximum leverage ratio, a minimum fixed charge coverage ratio, a maximum unsecured leverage ratio and a minimum tangible net worth requirement. As of March 31, 2019 , the Company was in compliance with all applicable financial covenants under the Credit Facility. Interest Expense During the three months ended March 31, 2019 and 2018 , the Company incurred interest expense of $36.3 million and $35.8 million , respectively. Interest expense includes non-cash interest expense of $2.6 million and $2.5 million for the three months ended March 31, 2019 and 2018 , respectively. As of March 31, 2019 and December 31, 2018 , the Company had $15.6 million and $24.0 million , respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets. Maturities The following is a schedule of maturities for the Company’s outstanding debt as of March 31, 2019 (in thousands): Secured Indebtedness Revolving Credit Facility (1) Term Loans Senior Notes Total April 1 through December 31, 2019 $ 2,584 $ — $ — $ — $ 2,584 2020 3,541 — 200,000 — 203,541 2021 18,446 620,000 — 500,000 1,138,446 2022 3,185 — 993,625 — 996,810 2023 3,282 — — 200,000 203,282 Thereafter 85,916 — — 600,000 685,916 Total Debt 116,954 620,000 1,193,625 1,300,000 3,230,579 Premium, net — — — 14,135 14,135 Deferred financing costs, net (1,766 ) — (6,241 ) (6,477 ) (14,484 ) Total Debt, Net $ 115,188 $ 620,000 $ 1,187,384 $ 1,307,658 $ 3,230,230 (1) Revolving Credit Facility is subject to two six -month extension options.

DERIVATIVE AND HEDGING INSTRUME

DERIVATIVE AND HEDGING INSTRUMENTS	3 Months Ended
	Mar. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE AND HEDGING INSTRUMENTS	DERIVATIVE AND HEDGING INSTRUMENTS The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company’s derivative financial instruments are used to manage differences in the amount of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings. Certain of the Company’s foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company’s functional currency, the U.S. dollar, of the Company’s investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes. Cash Flow Hedges The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. As of March 31, 2019 , approximately $6.7 million of gains, which are included in accumulated other comprehensive income, are expected to be reclassified into earnings in the next 12 months. Net Investment Hedges The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments. The following presents the notional amount of derivative instruments as of the dates indicated (in thousands): March 31, 2019 December 31, 2018 Derivatives designated as cash flow hedges: Denominated in U.S. Dollars (1) $ 1,100,000 $ 1,045,000 Denominated in Canadian Dollars $ 125,000 $ 125,000 Derivatives designated as net investment hedges: Denominated in Canadian Dollars $ 56,050 $ 55,401 Financial instrument designated as net investment hedge: Denominated in Canadian Dollars $ 125,000 $ 125,000 Derivatives not designated as net investment hedges: Denominated in Canadian Dollars $ 250 $ 899 (1) Balance includes forward starting interest rate swaps having an effective date of June 2019 that were entered into as of March 31, 2019 to hedge $255.0 million of anticipated fixed-rate debt issuance to occur sometime during 2019. Derivative and Financial Instruments Designated as Hedging Instruments The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at March 31, 2019 and December 31, 2018 (dollars in thousands): Count as of March 31, 2019 Fair Value Maturity Dates Type Designation March 31, 2019 December 31, 2018 Balance Sheet Location Assets: Interest rate swaps Cash flow 12 $ 18,057 $ 25,184 2020 - 2023 Accounts receivable, prepaid expenses and other assets, net Cross currency interest rate swaps Net investment 2 2,883 4,160 2025 Accounts receivable, prepaid expenses and other assets, net $ 20,940 $ 29,344 Liabilities: Forward starting interest rate swaps Cash flow 3 $ 11,926 $ 4,529 2029 Accounts payable and accrued liabilities CAD term loan Net investment 1 93,625 91,700 2022 Term loans, net $ 105,551 $ 96,229 The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the condensed consolidated statements of income and the condensed consolidated statements of equity for the three months ended March 31, 2019 and 2018 (in thousands): (Loss) Gain Recognized in Other Comprehensive (Loss) Income Three Months Ended March 31, 2019 2018 Income Statement Location Cash Flow Hedges: Interest rate products $ (11,611 ) $ 9,123 Interest expense Net Investment Hedges: Foreign currency products (1,234 ) 607 N/A CAD term loan (1,925 ) 2,675 N/A $ (14,770 ) $ 12,405 Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income Three Months Ended March 31, 2019 2018 Income Statement Location Cash Flow Hedges: Interest rate products $ 1,913 $ (50 ) Interest expense The gain (loss) in the table above related to interest rate products was reclassified from accumulated other comprehensive income into interest expense. Interest expense totaled $36.3 million and $35.8 million for the three months ended March 31, 2019 and 2018 , respectively. During the three months ended March 31, 2019 and 2018 , no cash flow hedges were determined to be ineffective. Derivatives Not Designated as Hedging Instruments As of March 31, 2019 , the Company had one outstanding cross currency interest rate swap not designated as a hedging instrument in an asset position with a fair value of $13,000 and included this amount in accounts receivable, prepaid expenses and other assets, net on the condensed consolidated balance sheets. During the three months ended March 31, 2019 , the Company recorded $6,000 of other expense related to this derivative not designated as a hedging instrument. Offsetting Derivatives The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of March 31, 2019 and December 31, 2018 (in thousands): As of March 31, 2019 Gross Amounts of Recognized Assets / Liabilities Gross Amounts Offset in the Balance Sheet Net Amounts of Assets / Liabilities presented in the Balance Sheet Gross Amounts Not Offset in the Balance Sheet Financial Instruments Cash Collateral Received Net Amount Offsetting Assets: Derivatives $ 20,940 $ — $ 20,940 $ (6,349 ) $ — $ 14,591 Offsetting Liabilities: Derivatives $ 11,926 $ — $ 11,926 $ (6,349 ) $ — $ 5,577 As of December 31, 2018 Gross Amounts of Recognized Assets / Liabilities Gross Amounts Offset in the Balance Sheet Net Amounts of Assets / Liabilities presented in the Balance Sheet Gross Amounts Not Offset in the Balance Sheet Financial Instruments Cash Collateral Received Net Amount Offsetting Assets: Derivatives $ 29,344 $ — $ 29,344 $ (2,069 ) $ — $ 27,275 Offsetting Liabilities: Derivatives $ 4,529 $ — $ 4,529 $ (2,069 ) $ — $ 2,460 Credit-risk-related Contingent Features The Company has agreements with each of its derivative counterparties that contain a provision pursuant to which the Company could be declared in default on the derivative obligation if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender. As of March 31, 2019 , the fair value of derivatives in a net liability position, which includes accrued interest but excludes any adjustment for nonperformance risk, related to these agreements was $5.3 million . As of March 31, 2019 , the Company has not posted any collateral related to these agreements. If the Company had breached any of these provisions at March 31, 2019 , it could have been required to settle its obligations under the agreements at their termination value of $5.3 million .

FAIR VALUE DISCLOSURES

FAIR VALUE DISCLOSURES	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
FAIR VALUE DISCLOSURES	FAIR VALUE DISCLOSURES Financial Instruments The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments. Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Facility are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows: Loans receivable : These instruments are presented on the accompanying condensed consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. As such, the Company classifies these instruments as Level 3. Preferred equity investments : These instruments are presented on the accompanying condensed consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. As such, the Company classifies these instruments as Level 3. Derivative instruments : The Company’s derivative instruments are presented at fair value on the accompanying condensed consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy. Senior Notes : These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2. Secured indebtedness : These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. As such, the Company classifies these instruments as Level 3. The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of March 31, 2019 and December 31, 2018 whose carrying amounts do not approximate their fair value (in thousands): March 31, 2019 December 31, 2018 Face (1) Carrying Amount (2) Fair Value Face (1) Carrying (2) Fair Value Financial assets: Loans receivable $ 71,520 $ 65,789 $ 66,146 $ 96,492 $ 69,460 $ 65,797 Preferred equity investments 43,014 43,425 43,834 43,851 44,262 43,825 Financial liabilities: Senior Notes 1,300,000 1,307,658 1,301,575 1,300,000 1,307,394 1,270,877 Secured indebtedness 116,954 115,188 104,244 117,464 115,679 101,820 (1) Face value represents amounts contractually due under the terms of the respective agreements. (2) Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs. The Company determined the fair value of financial instruments as of March 31, 2019 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands): Fair Value Measurements Using Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Financial assets: Loans receivable $ 66,146 $ — $ — $ 66,146 Preferred equity investments 43,834 — — 43,834 Financial liabilities: Senior Notes 1,301,575 — 1,301,575 — Secured indebtedness 104,244 — — 104,244 Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Despite increased capital market and credit market activity, transaction volume for certain financial instruments remains relatively low. This has made the estimation of fair values difficult and, therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different. Items Measured at Fair Value on a Recurring Basis During the three months ended March 31, 2019 , the Company recorded the following amounts measured at fair value (in thousands): Fair Value Measurements Using Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Recurring Basis: Financial assets: Interest rate swap $ 18,057 $ — $ 18,057 $ — Cross currency swap 2,883 — 2,883 — Financial liabilities: Interest rate swap 11,926 — 11,926 —

EQUITY

EQUITY	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
EQUITY	EQUITY Preferred Stock On March 21, 2013, the Company completed an underwritten public offering of 5,750,000 shares of 7.125% Series A Cumulative Redeemable Preferred Stock (the “Series A Preferred Stock”) at a price of $25.00 per share, pursuant to an effective registration statement. The Company redeemed all 5,750,000 shares of its Series A Preferred Stock on June 1, 2018 (the “Redemption Date”) for $25.00 per share, plus accrued and unpaid dividends to, but not including, the Redemption Date, without interest, in the amount of $0.4453125 per share of Series A Preferred Stock, for a total redemption price per share of Series A Preferred Stock equal to $25.4453125 . As a result of the redemption, the Company incurred a charge of $5.5 million related to the original issuance costs of the Series A Preferred Stock during the three months ended June 30, 2018. Common Stock On February 25, 2019, the Company entered into an equity distribution agreement (the “Distribution Agreement”) with a consortium of banks acting as sales agents (the “Sales Agents”) to sell shares of its common stock having aggregate gross proceeds of up to $500.0 million from time to time through the Sales Agents (the “ATM Program”). Pursuant to the terms of the Distribution Agreement, the shares may be sold by any method permitted by law deemed to be an “at-the-market” offering, including, without limitation, sales made directly on the Nasdaq Global Select Market, on any other existing trading market for the Company’s common stock or to or through a market maker (which may include block transactions). In addition, with the Company’s prior consent, the Sales Agents may also sell the shares in privately negotiated transactions. The Company will pay each Sales Agent a commission of up to 1.5% of the gross proceeds from the sales of shares sold pursuant to the Distribution Agreement. The offering of shares pursuant to the Distribution Agreement will terminate upon the earlier of (i) the sale of the maximum aggregate amount of the shares subject to the Distribution Agreement, or (ii) the termination of the Distribution Agreement as permitted therein. The offering of shares pursuant to the Distribution Agreement may also be suspended as permitted therein. The Company sold no shares under the ATM Program during the three months ended March 31, 2019 . As of March 31, 2019 , the Company had $500.0 million available under the ATM Program. The following table lists the cash dividends on common stock declared and paid by the Company during the three months ended March 31, 2019 : Declaration Date Record Date Amount Per Share Dividend Payable Date February 5, 2019 February 15, 2019 $ 0.45 February 28, 2019 During the three months ended March 31, 2019 , the Company issued 113,071 shares of common stock as a result of restricted stock unit vestings. Upon any payment of shares to employees as a result of restricted stock unit vestings, the employees’ related tax withholding obligation will generally be satisfied by the Company, reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the three months ended March 31, 2019 and 2018 , the Company incurred $1.3 million and $0.2 million , respectively, in tax withholding obligations on behalf of its employees that were satisfied through a reduction in the number of shares delivered to those participants. Accumulated Other Comprehensive (Loss) Income The following is a summary of the Company’s accumulated other comprehensive (loss) income (in thousands): March 31, 2019 December 31, 2018 Foreign currency translation loss $ (2,753 ) $ (2,193 ) Unrealized gains on cash flow hedges 1,006 14,494 Total accumulated other comprehensive (loss) income $ (1,747 ) $ 12,301

EARNINGS PER COMMON SHARE

EARNINGS PER COMMON SHARE	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
EARNINGS PER COMMON SHARE	EARNINGS PER COMMON SHARE The following table illustrates the computation of basic and diluted earnings per share for the three months ended March 31, 2019 and 2018 (in thousands, except share and per share amounts): Three Months Ended March 31, 2019 2018 Numerator Net (loss) income attributable to common stockholders $ (77,704 ) $ 59,910 Denominator Basic weighted average common shares and common equivalents 178,385,984 178,294,605 Dilutive restricted stock units — 221,783 Diluted weighted average common shares 178,385,984 178,516,388 Net (loss) income attributable to common stockholders, per: Basic common share $ (0.44 ) $ 0.34 Diluted common share $ (0.44 ) $ 0.34 During the three months ended March 31, 2019 and 2018 , approximately 3,100 and 21,400 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive. No stock options were considered anti-dilutive during the three months ended March 31, 2019 and 2018 .

SUMMARIZED CONDENSED CONSOLIDAT

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION	3 Months Ended
	Mar. 31, 2019
Summarized Condensed Consolidating Information [Abstract]
SUMMARIZED CONDENSED CONSOLIDATING INFORMATION	SUMMARIZED CONDENSED CONSOLIDATING INFORMATION In connection with the offerings of the 2021 Notes and the 2023 Notes by the Issuers, the Company and certain 100% owned subsidiaries of the Company (the “Guarantors”) have, jointly and severally, fully and unconditionally guaranteed the 2021 Notes and the 2023 Notes, subject to release under certain customary circumstances as described below. In connection with the assumption of the 2026 Notes as a result of the CCP Merger, the Company has fully and unconditionally guaranteed the 2026 Notes, subject to release under certain circumstances as described below. These guarantees are subordinated to all existing and future senior debt and senior guarantees of the Guarantors and are unsecured. The Company conducts all of its business through and derives virtually all of its income from its subsidiaries. Therefore, the Company’s ability to make required payments with respect to its indebtedness (including the Senior Notes) and other obligations depends on the financial results and condition of its subsidiaries and its ability to receive funds from its subsidiaries. A Guarantor will be automatically and unconditionally released from its obligations under the guarantees with respect to the 2021 Notes and the 2023 Notes in the event of: • Any sale of the subsidiary Guarantor or of all or substantially all of its assets; • A merger or consolidation of a subsidiary Guarantor with an issuer of the 2021 Notes or the 2023 Notes or another Guarantor, provided that the surviving entity remains a Guarantor; • A subsidiary Guarantor is declared “unrestricted” for covenant purposes under the indentures governing the 2021 Notes or the 2023 Notes; • The requirements for legal defeasance or covenant defeasance or to discharge the indentures governing the 2021 Notes or the 2023 Notes have been satisfied; • A liquidation or dissolution, to the extent permitted under the indentures governing the 2021 Notes or the 2023 Notes, of a subsidiary Guarantor; or • The release or discharge of the guaranty that resulted in the creation of the subsidiary guaranty, except a discharge or release by or as a result of payment under such guaranty. The Company will be automatically and unconditionally released from its obligations under the guarantees with respect to the 2026 Notes in the event of: • A liquidation or dissolution, to the extent permitted under the indenture governing the 2026 Notes; • A merger or consolidation, provided that the surviving entity remains a Guarantor; or • The requirements for legal defeasance or covenant defeasance or to discharge the indenture governing the 2026 Notes have been satisfied. Pursuant to Rule 3-10 of Regulation S-X, the following summarized condensed consolidating information is provided for the Company (the “Parent Company”), the Operating Partnership, Sabra Capital Corporation, the Guarantors, and the Company’s non-Guarantor subsidiaries with respect to the 2021 Notes and the 2023 Notes. This summarized financial information has been prepared from the books and records maintained by the Company, the Operating Partnership, Sabra Capital Corporation, the Guarantors and the non-Guarantor subsidiaries. The summarized financial information may not necessarily be indicative of the results of operations or financial position had the Operating Partnership, Sabra Capital Corporation, the Guarantors or non-Guarantor subsidiaries operated as independent entities. Sabra’s investments in its consolidated subsidiaries are presented based upon Sabra’s proportionate share of each subsidiary’s net assets. The Guarantor subsidiaries’ investments in the non-Guarantor subsidiaries and non-Guarantor subsidiaries’ investments in Guarantor subsidiaries are presented under the equity method of accounting. Intercompany activities between subsidiaries and the Parent Company are presented within operating activities on the condensed consolidating statement of cash flows. Condensed consolidating financial statements for the Company and its subsidiaries, including the Parent Company only, the Operating Partnership only, Sabra Capital Corporation only, the combined Guarantor subsidiaries and the combined non-Guarantor subsidiaries, are as follows: CONDENSED CONSOLIDATING BALANCE SHEET March 31, 2019 (in thousands) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Assets Real estate investments, net of accumulated depreciation $ 306 $ — $ — $ 1,597,664 $ 3,839,384 $ — $ 5,437,354 Loans receivable and other investments, net (533 ) — — 49,730 60,017 — 109,214 Investment in unconsolidated joint venture — — — — 335,701 — 335,701 Cash and cash equivalents 14,770 — — 1,570 6,533 — 22,873 Restricted cash — — — 1,845 7,921 — 9,766 Assets held for sale — — — — 270,780 — 270,780 Lease intangible assets, net — — — 15,469 104,198 — 119,667 Accounts receivable, prepaid expenses and other assets, net 5,171 27,962 — 30,770 92,782 (6,895 ) 149,790 Intercompany 1,893,948 2,619,046 — — — (4,512,994 ) — Investment in subsidiaries 1,155,457 1,558,253 — 32,540 — (2,746,250 ) — Total assets $ 3,069,119 $ 4,205,261 $ — $ 1,729,588 $ 4,717,316 $ (7,266,139 ) $ 6,455,145 Liabilities Secured debt, net $ — $ — $ — $ — $ 115,188 $ — $ 115,188 Revolving credit facility — 620,000 — — — — 620,000 Term loans, net — 1,094,639 — 92,745 — — 1,187,384 Senior unsecured notes, net — 1,307,658 — — — — 1,307,658 Accounts payable and accrued liabilities 22,650 27,507 — 3,344 48,203 (6,895 ) 94,809 Lease intangible liabilities, net — — — — 79,328 — 79,328 Intercompany — — — 350,674 4,162,320 (4,512,994 ) — Total liabilities 22,650 3,049,804 — 446,763 4,405,039 (4,519,889 ) 3,404,367 Total Sabra Health Care REIT, Inc. stockholders’ equity 3,046,469 1,155,457 — 1,282,825 307,968 (2,746,250 ) 3,046,469 Noncontrolling interests — — — — 4,309 — 4,309 Total equity 3,046,469 1,155,457 — 1,282,825 312,277 (2,746,250 ) 3,050,778 Total liabilities and equity $ 3,069,119 $ 4,205,261 $ — $ 1,729,588 $ 4,717,316 $ (7,266,139 ) $ 6,455,145 (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes. CONDENSED CONSOLIDATING BALANCE SHEET December 31, 2018 (in thousands) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Assets Real estate investments, net of accumulated depreciation $ 317 $ — $ — $ 1,609,861 $ 4,243,367 $ — $ 5,853,545 Loans receivable and other investments, net (560 ) — — 50,534 63,748 — 113,722 Investment in unconsolidated joint venture — — — — 340,120 — 340,120 Cash and cash equivalents 40,835 — — 3,508 5,887 — 50,230 Restricted cash — — — 1,820 7,608 — 9,428 Lease intangible assets, net — — — 15,892 115,205 — 131,097 Accounts receivable, prepaid expenses and other assets, net 798 37,075 — 58,710 81,597 (11,019 ) 167,161 Intercompany 1,972,059 2,646,669 — — — (4,618,728 ) — Investment in subsidiaries 1,258,715 1,629,795 — 33,083 — (2,921,593 ) — Total assets $ 3,272,164 $ 4,313,539 $ — $ 1,773,408 $ 4,857,532 $ (7,551,340 ) $ 6,665,303 Liabilities Secured debt, net $ — $ — $ — $ — $ 115,679 $ — $ 115,679 Revolving credit facility — 624,000 — — — — 624,000 Term loans, net — 1,094,177 — 90,753 — — 1,184,930 Senior unsecured notes, net — 1,307,394 — — — — 1,307,394 Accounts payable and accrued liabilities 21,750 29,253 — 2,695 52,148 (11,019 ) 94,827 Lease intangible liabilities, net — — — — 83,726 — 83,726 Intercompany — — — 399,912 4,218,816 (4,618,728 ) — Total liabilities 21,750 3,054,824 — 493,360 4,470,369 (4,629,747 ) 3,410,556 Total Sabra Health Care REIT, Inc. stockholders’ equity 3,250,414 1,258,715 — 1,280,048 382,830 (2,921,593 ) 3,250,414 Noncontrolling interests — — — — 4,333 — 4,333 Total equity 3,250,414 1,258,715 — 1,280,048 387,163 (2,921,593 ) 3,254,747 Total liabilities and equity $ 3,272,164 $ 4,313,539 $ — $ 1,773,408 $ 4,857,532 $ (7,551,340 ) $ 6,665,303 (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes. CONDENSED CONSOLIDATING STATEMENT OF (LOSS) INCOME For the Three Months Ended March 31, 2019 (dollars in thousands, except per share amounts) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Revenues: Rental and related revenues $ — $ — $ — $ 32,125 $ 88,638 $ (4,376 ) $ 116,387 Interest and other income 29 96 — 1,231 2,065 (96 ) 3,325 Resident fees and services — — — — 17,061 — 17,061 Total revenues 29 96 — 33,356 107,764 (4,472 ) 136,773 Expenses: Depreciation and amortization 12 — — 12,888 32,049 — 44,949 Interest — 34,275 — 903 1,236 (96 ) 36,318 Triple-net portfolio operating expenses — — — 1,014 4,275 — 5,289 Senior Housing - Managed portfolio operating expenses — — — — 16,416 (4,376 ) 12,040 General and administrative 7,525 31 — 167 455 — 8,178 Merger and acquisition costs 6 — — — — — 6 (Recovery of) provision for doubtful accounts, straight-line rental income and loan losses (27 ) — — — 1,234 — 1,207 Impairment of real estate — — — — 103,134 — 103,134 Total expenses 7,516 34,306 — 14,972 158,799 (4,472 ) 211,121 Other (expense) income: Other (expense) income — (498 ) — 492 177 — 171 Net loss on sales of real estate — — — (375 ) (1,145 ) — (1,520 ) Total other (expense) income — (498 ) — 117 (968 ) — (1,349 ) (Loss) income in subsidiary (69,777 ) (35,068 ) — 1,668 — 103,177 — (Loss) income before loss from unconsolidated joint venture and income tax expense (77,264 ) (69,776 ) — 20,169 (52,003 ) 103,177 (75,697 ) Loss from unconsolidated joint venture — — — — (1,383 ) — (1,383 ) Income tax expense (440 ) (1 ) — (105 ) (66 ) — (612 ) Net (loss) income (77,704 ) (69,777 ) — 20,064 (53,452 ) 103,177 (77,692 ) Net income attributable to noncontrolling interests — — — — (12 ) — (12 ) Net (loss) income attributable to common stockholders $ (77,704 ) $ (69,777 ) $ — $ 20,064 $ (53,464 ) $ 103,177 $ (77,704 ) Net loss attributable to common stockholders, per: Basic common share $ (0.44 ) Diluted common share $ (0.44 ) Weighted-average number of common shares outstanding, basic 178,385,984 Weighted-average number of common shares outstanding, diluted 178,385,984 (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes. CONDENSED CONSOLIDATING STATEMENT OF INCOME For the Three Months Ended March 31, 2018 (dollars in thousands, except per share amounts) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Revenues: Rental and related revenues $ — $ — $ — $ 45,464 $ 103,024 $ (4,233 ) $ 144,255 Interest and other income 10 112 — 1,267 3,061 (112 ) 4,338 Resident fees and services — — — — 17,493 — 17,493 Total revenues 10 112 — 46,731 123,578 (4,345 ) 166,086 Expenses: Depreciation and amortization 222 — — 14,930 32,853 — 48,005 Interest — 32,566 — 790 2,574 (112 ) 35,818 Senior Housing - Managed portfolio operating expenses — — — — 16,357 (4,233 ) 12,124 General and administrative 5,822 14 — 431 1,600 — 7,867 Merger and acquisition costs 336 — — — (6 ) — 330 Provision for (recovery of) doubtful accounts, straight-line rental income and loan losses 2,181 — — (971 ) 3 — 1,213 Impairment of real estate — — — 532 — — 532 Total expenses 8,561 32,580 — 15,712 53,381 (4,345 ) 105,889 Other income (expense): Other income 1,977 201 — 410 232 — 2,820 Net loss on sales of real estate — — — (56 ) (416 ) — (472 ) Total other income (expense) 1,977 201 — 354 (184 ) — 2,348 Income in subsidiary 69,343 101,610 — 1,854 — (172,807 ) — Income before income from unconsolidated joint venture and income tax expense 62,769 69,343 — 33,227 70,013 (172,807 ) 62,545 Income from unconsolidated joint venture — — — — 446 — 446 Income tax expense (298 ) — — (53 ) (159 ) — (510 ) Net income 62,471 69,343 — 33,174 70,300 (172,807 ) 62,481 Net income attributable to noncontrolling interests — — — — (10 ) — (10 ) Net income attributable to Sabra Health Care REIT, Inc. 62,471 69,343 — 33,174 70,290 (172,807 ) 62,471 Preferred stock dividends (2,561 ) — — — — — (2,561 ) Net income attributable to common stockholders $ 59,910 $ 69,343 $ — $ 33,174 $ 70,290 $ (172,807 ) $ 59,910 Net income attributable to common stockholders, per: Basic common share $ 0.34 Diluted common share $ 0.34 Weighted-average number of common shares outstanding, basic 178,294,605 Weighted-average number of common shares outstanding, diluted 178,516,388 (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes. CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE (LOSS) INCOME For the Three Months Ended March 31, 2019 (dollars in thousands) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Net (loss) income $ (77,704 ) $ (69,777 ) $ — $ 20,064 $ (53,452 ) $ 103,177 $ (77,692 ) Other comprehensive income (loss): Unrealized gain (loss), net of tax: Foreign currency translation (loss) gain — (1,437 ) — 678 199 — (560 ) Unrealized loss on cash flow hedges — (13,486 ) — (2 ) — — (13,488 ) Total other comprehensive (loss) income — (14,923 ) — 676 199 — (14,048 ) Comprehensive (loss) income (77,704 ) (84,700 ) — 20,740 (53,253 ) 103,177 (91,740 ) Comprehensive income attributable to noncontrolling interest — — — — (12 ) — (12 ) Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc. $ (77,704 ) $ (84,700 ) $ — $ 20,740 $ (53,265 ) $ 103,177 $ (91,752 ) (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes. CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME For the Three Months Ended March 31, 2018 (dollars in thousands) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Net income $ 62,471 $ 69,343 $ — $ 33,174 $ 70,300 $ (172,807 ) $ 62,481 Other comprehensive income (loss): Unrealized gain (loss), net of tax: Foreign currency translation gain (loss) — 841 — (928 ) (287 ) — (374 ) Unrealized gain (loss) on cash flow hedges — 9,903 — (5 ) — — 9,898 Total other comprehensive income (loss) — 10,744 — (933 ) (287 ) — 9,524 Comprehensive income 62,471 80,087 — 32,241 70,013 (172,807 ) 72,005 Comprehensive income attributable to noncontrolling interest — — — — (10 ) — (10 ) Comprehensive income attributable to Sabra Health Care REIT, Inc. $ 62,471 $ 80,087 $ — $ 32,241 $ 70,003 $ (172,807 ) $ 71,995 (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes. CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2019 (in thousands) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Net cash provided by (used in) operating activities $ 49,833 $ — $ — $ (379 ) $ 4,505 $ — $ 53,959 Cash flows from investing activities: Origination and fundings of loans receivable — — — (352 ) (2,424 ) — (2,776 ) Additions to real estate — — — (1,936 ) (3,136 ) — (5,072 ) Repayments of loans receivable — — — 61 5,190 — 5,251 Repayments of preferred equity investments — — — 2,087 — — 2,087 Net proceeds from the sales of real estate — — — 3,829 3,028 — 6,857 Distribution from subsidiaries 2,569 2,569 — — — (5,138 ) — Intercompany financing 4,116 8,122 — — — (12,238 ) — Net cash provided by investing activities 6,685 10,691 — 3,689 2,658 (17,376 ) 6,347 Cash flows from financing activities: Net repayments of revolving credit facility — (4,000 ) — — — — (4,000 ) Principal payments on secured debt — — — — (849 ) — (849 ) Payments of deferred financing costs — (6 ) — — — — (6 ) Distributions to noncontrolling interest — — — — (36 ) — (36 ) Issuance of common stock, net (2,323 ) — — — — — (2,323 ) Dividends paid on common stock (80,260 ) — — — — — (80,260 ) Distribution to parent — (2,569 ) — — (2,569 ) 5,138 — Intercompany financing — (4,116 ) — (5,331 ) (2,791 ) 12,238 — Net cash used in financing activities (82,583 ) (10,691 ) — (5,331 ) (6,245 ) 17,376 (87,474 ) Net (decrease) increase in cash, cash equivalents and restricted cash (26,065 ) — — (2,021 ) 918 — (27,168 ) Effect of foreign currency translation on cash, cash equivalents and restricted cash — — — 108 41 — 149 Cash, cash equivalents and restricted cash, beginning of period 40,835 — — 5,328 13,495 — 59,658 Cash, cash equivalents and restricted cash, end of period $ 14,770 $ — $ — $ 3,415 $ 14,454 $ — $ 32,639 (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes. CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2018 (in thousands) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Net cash provided by (used in) operating activities $ 97,936 $ — $ — $ (55 ) $ 3,766 $ — $ 101,647 Cash flows from investing activities: Acquisition of real estate — — — (172,001 ) — — (172,001 ) Origination and fundings of loans receivable — — — (1,027 ) (12,205 ) — (13,232 ) Origination and fundings of preferred equity investments — — — (928 ) — — (928 ) Additions to real estate (38 ) — — (3,496 ) (8,005 ) — (11,539 ) Repayments of loans receivable — — — 7,491 21,314 — 28,805 Repayments of preferred equity investments — — — 234 — — 234 Investment in unconsolidated JV — — — — (354,461 ) — (354,461 ) Net proceeds from the sales of real estate — — — — 6,743 — 6,743 Distribution from subsidiaries 2,557 2,557 — — — (5,114 ) — Intercompany financing (488,718 ) (458,712 ) — — — 947,430 — Net cash (used in) provided by investing activities (486,199 ) (456,155 ) — (169,727 ) (346,614 ) 942,316 (516,379 ) Cash flows from financing activities: Net repayments of revolving credit facility — (30,000 ) — — — — (30,000 ) Principal payments on secured debt — — — — (1,061 ) — (1,061 ) Payments of deferred financing costs — (6 ) — — — — (6 ) Distribution to noncontrolling interest — — — — (37 ) — (37 ) Issuance of common stock, net (499 ) — — — — — (499 ) Dividends paid on common and preferred stock (82,789 ) — — — — — (82,789 ) Distribution to parent — (2,557 ) — — (2,557 ) 5,114 — Intercompany financing — 488,718 — 134,797 323,915 (947,430 ) — Net cash (used in) provided by financing activities (83,288 ) 456,155 — 134,797 320,260 (942,316 ) (114,392 ) Net decrease in cash, cash equivalents and restricted cash (471,551 ) — — (34,985 ) (22,588 ) — (529,124 ) Effect of foreign currency translation on cash, cash equivalents and restricted cash — — — (72 ) (83 ) — (155 ) Cash, cash equivalents and restricted cash, beginning of period 511,670 — — 37,359 38,420 — 587,449 Cash, cash equivalents and restricted cash, end of period $ 40,119 $ — $ — $ 2,302 $ 15,749 $ — $ 58,170 (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Environmental As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of March 31, 2019 , the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations. Legal Matters From time to time, the Company is party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company’s results of operations, financial condition or cash flows.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued. Dividend Declaration On May 8, 2019 , the Company announced that its board of directors declared a quarterly cash dividend of $0.45 per share of common stock. The dividend will be paid on May 31, 2019 to common stockholders of record as of the close of business on May 20, 2019 .

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Accounting	The accompanying condensed consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of March 31, 2019 and December 31, 2018 and for the three month periods ended March 31, 2019 and 2018 . All significant intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019 . For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC.
Variable Interest Entities	GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary. The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of March 31, 2019 , the Company determined that it was the primary beneficiary of one VIE—a joint venture variable interest entity owning one skilled nursing/transitional care facility—and has consolidated the operations of this entity in the accompanying condensed consolidated financial statements. As of March 31, 2019 , the Company determined that the operations of this entity were not material to the Company’s results of operations, financial condition or cash flows. As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At March 31, 2019 , none of the Company’s investments in loans were accounted for as real estate joint ventures. As it relates to investments in joint ventures, the Company assesses any limited partners’ rights and their impact on the presumption of control of the limited partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the sole general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests.
Use of Estimates	The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.
Investment in Unconsolidated Joint Venture	The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company’s share of the investee’s earnings or losses is included in the Company’s condensed consolidated statements of income. The initial carrying value of the investment is based on the amount paid to purchase the joint venture interest. Differences between the Company’s cost basis and the basis reflected at the joint venture level are generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company’s share of earnings of the joint venture. The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its equity method investments may not be recoverable or realized. When indicators of potential impairment are identified, the Company evaluates its equity method investments for impairment based on a comparison of the fair value of the investment to its carrying value. The fair value is estimated based on discounted cash flows that include all estimated cash inflows and outflows over a specified holding period and any estimated debt premiums or discounts. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its equity method investment, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its equity method investment.
Net Investment in Direct Financing Lease	The net investment in direct financing lease is recorded in accounts receivable, prepaid expenses and other assets, net on the accompanying condensed consolidated balance sheets and represents the total undiscounted rental payments of $5.2 million , plus the estimated unguaranteed residual value of $24.7 million , less the unearned lease income of $6.4 million as of March 31, 2019 . Unearned lease income represents the excess of the minimum lease payments and residual value over the cost of the investment. Unearned lease income is deferred and amortized to income over the lease term to provide a constant yield when collectability of the lease payments is reasonably assured.
Recently Issued Accounting Standards Update	Adopted In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases, as amended by subsequent ASUs (“Topic 842”). Topic 842 supersedes guidance related to accounting for leases and provides for the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. The objective of Topic 842 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a lease. Topic 842 does not fundamentally change lessor accounting; however, some changes have been made to lessor accounting to conform and align that guidance with the lessee guidance and other areas within GAAP. Topic 842 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company elected to adopt Topic 842 on January 1, 2019 using the modified retrospective transition method, which permits application of the new standard on the adoption date as opposed to the earliest comparative period presented in the financial statements. In addition, the Company elected to use the available practical expedient package, and therefore did not reassess classification of its existing leases. Additionally, the Company has elected a practical expedient not to separate lease and nonlease components (such as services rendered), which can only be applied to leasing arrangements for which (i) the timing and pattern of transfer are the same for the lease and nonlease components and (ii) the lease component, if accounted for separately, would be classified as an operating lease. Under this practical expedient, contracts that are predominantly lease-based would be accounted for under Topic 842, and contracts that are predominantly service-based would be accounted for under Topic 606, Revenue from Contracts with Customers. As a result of electing this practical expedient, the Company, beginning January 1, 2019, recognizes revenue from its leased skilled nursing/transitional care facilities, senior housing communities, and specialty hospitals and other facilities under Topic 842 and recognizes revenue from its Senior Housing - Managed communities under the Revenue ASUs (codified under Topic 606). Upon adoption of Topic 842, the Company recognized its operating leases for which it is the lessee, mainly its corporate office lease and ground leases, on its consolidated balance sheets, as a lease liability of $10.0 million , included in accounts payable and accrued liabilities on the condensed consolidated balance sheets, and a corresponding right-of-use asset, included in accounts receivable, prepaid expenses and other assets, net on the condensed consolidated balance sheets. As of March 31, 2019 , the balances of the lease liability and the corresponding right-of-use asset were $10.0 million and $9.8 million , respectively. The Company assesses the collectability of rental revenues on a lease-by-lease basis. Prior to the adoption of Topic 842, the Company recorded rental revenue and receivables to the extent those amounts were expected to be collected, irrespective of the Company’s determination of the collectability of substantially all rents over the life of a lease. Upon adoption of Topic 842, if at any time the Company cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received and all receivables associated with the lease will be written off irrespective of amounts expected to be collectible. Upon adoption of Topic 842 and as of the adoption date, the Company recorded a $32.5 million reduction in equity and accounts receivable due to the cumulative effect of this change. This reduction consisted of $17.5 million of straight-line rental income receivables and $15.0 million of cash rent receivables, although management believes the $15.0 million of cash rent receivables are collectible. Any recoveries of these amounts will be recorded in future periods upon receipt of payment. Under Topic 842, future write-offs of receivables and any recoveries of previously written-off receivables will be recorded as adjustments to rental revenue. Furthermore, Topic 842 requires lessors to exclude from variable payments lessor costs paid by lessees directly to third parties. In contrast, lessor costs that are paid by the lessor and reimbursed by the lessee are included in the measurement of variable lease revenue and the associated expense. As a result, the Company recognized $4.2 million of variable lease revenue and the associated expense during the three months ended March 31, 2019 . Issued but Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires that a financial asset (or a group of financial assets) measured at amortized cost basis be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The amendments in ASU 2016-13 are an improvement because they eliminate the probable initial recognition threshold under current GAAP and, instead, reflect an entity’s current estimate of all expected credit losses. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. In November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2018-19”), which amends ASU 2016-13 to clarify that receivables arising from operating leases are not within the scope of Subtopic 326-20, and instead, impairment of such receivables should be accounted for in accordance with Topic 842, Leases. ASU 2016-13 and ASU 2018-19 are effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted as of the fiscal years beginning after December 15, 2018. An entity will apply the amendments in these updates through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). ASU 2018-13 updates the fair value measurement disclosure requirements by (i) eliminating certain requirements, including disclosure of the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and the valuation processes for Level 3 fair value measurements, (ii) modifying certain requirements, including clarifying that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date and (iii) adding certain requirements, including disclosure of the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted for any eliminated or modified disclosures. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted.
Fair Value of Financial Instruments	The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments. Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Facility are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows: Loans receivable : These instruments are presented on the accompanying condensed consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. As such, the Company classifies these instruments as Level 3. Preferred equity investments : These instruments are presented on the accompanying condensed consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. As such, the Company classifies these instruments as Level 3. Derivative instruments : The Company’s derivative instruments are presented at fair value on the accompanying condensed consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy. Senior Notes : These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2. Secured indebtedness : These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. As such, the Company classifies these instruments as Level 3.

RECENT REAL ESTATE ACQUISITIO_2

RECENT REAL ESTATE ACQUISITIONS (Tables)	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
Purchase Price Allocation	Allocation of the consideration was based on certain valuations and analyses and is as follows (in thousands): Three Months Ended March 31, 2018 Land $ 20,552 Building and improvements 150,523 Tenant origination and absorption costs intangible assets 722 Tenant relationship intangible assets 209 Total consideration $ 172,006

REAL ESTATE PROPERTIES HELD F_2

REAL ESTATE PROPERTIES HELD FOR INVESTMENT (Tables)	3 Months Ended
	Mar. 31, 2019
Real Estate Investments, Net [Abstract]
Real Estate Properties Held for Investment	The Company’s real estate properties held for investment consisted of the following (dollars in thousands): As of March 31, 2019 Property Type Number of Properties Number of Beds/Units Total Real Estate at Cost Accumulated Depreciation Total Real Estate Investments, Net Skilled Nursing/Transitional Care 304 34,049 $ 3,716,115 $ (234,633 ) $ 3,481,482 Senior Housing - Leased 88 7,147 1,220,158 (133,570 ) 1,086,588 Senior Housing - Managed 23 1,603 305,173 (22,037 ) 283,136 Specialty Hospitals and Other 22 1,085 621,236 (35,394 ) 585,842 437 43,884 5,862,682 (425,634 ) 5,437,048 Corporate Level 634 (328 ) 306 $ 5,863,316 $ (425,962 ) $ 5,437,354 As of December 31, 2018 Property Type Number of Properties Number of Beds/Units Total Real Estate at Cost Accumulated Depreciation Total Real Estate Investments, Net Skilled Nursing/Transitional Care 335 37,628 $ 4,094,484 $ (224,942 ) $ 3,869,542 Senior Housing - Leased 90 7,332 1,237,790 (125,902 ) 1,111,888 Senior Housing - Managed 23 1,603 301,739 (19,537 ) 282,202 Specialty Hospitals and Other 22 1,085 621,236 (31,640 ) 589,596 470 47,648 6,255,249 (402,021 ) 5,853,228 Corporate Level 634 (317 ) 317 $ 6,255,883 $ (402,338 ) $ 5,853,545 March 31, 2019 December 31, 2018 Building and improvements $ 5,044,382 $ 5,388,102 Furniture and equipment 221,123 237,145 Land improvements 1,317 1,254 Land 596,494 629,382 5,863,316 6,255,883 Accumulated depreciation (425,962 ) (402,338 ) $ 5,437,354 $ 5,853,545
Future Minimum Rental Payments Receivable for Properties Held for Investment Under Non-Cancelable Operating Leases	The future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows (in thousands): As of March 31, 2019 April 1 through December 31, 2019 $ 351,250 2020 456,660 2021 452,218 2022 454,086 2023 437,112 Thereafter 2,440,245 $ 4,591,571
Future Minimum Rental Payments Receivable for Properties Held for Investment Under Non-Cancelable Operating Leases	As of December 31, 2018 2019 $ 465,766 2020 456,207 2021 452,346 2022 454,216 2023 437,277 Thereafter 2,407,064 $ 4,672,876

LOANS RECEIVABLE AND OTHER IN_2

LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables)	3 Months Ended
	Mar. 31, 2019
Receivables [Abstract]
Loans Receivable and Other Investments	As of March 31, 2019 and December 31, 2018 , the Company’s loans receivable and other investments consisted of the following (dollars in thousands): March 31, 2019 Investment Quantity as of March 31, 2019 Property Type Principal Balance as of March 31, 2019 (1) Book Value as of March 31, 2019 Book Value as of Weighted Average Contractual Interest Rate / Rate of Return Weighted Average Annualized Effective Interest Rate / Rate of Return Maturity Date as of March 31, 2019 Loans Receivable: Mortgage 1 Specialty Hospital $ 19,000 $ 19,000 $ 18,577 10.0 % 10.0 % 01/31/27 Construction 2 Senior Housing 4,887 4,945 4,629 8.0 % 7.7 % 04/30/21- 09/30/22 Mezzanine — Skilled Nursing — — 2,188 N/A N/A N/A Other 17 Multiple 47,633 43,611 45,324 7.1 % 7.7 % 02/28/19- 08/31/28 20 71,520 67,556 70,718 7.9 % 8.4 % Loan loss reserve — (1,767 ) (1,258 ) $ 71,520 $ 65,789 $ 69,460 Other Investments: Preferred Equity 9 Skilled Nursing / Senior Housing 43,014 43,425 44,262 12.0 % 12.0 % N/A Total 29 $ 114,534 $ 109,214 $ 113,722 9.4 % 9.8 % (1) Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.
Changes in Accretable Yield of Loans with Deteriorated Credit Quality	The following table presents changes in the accretable yield for the three months ended March 31, 2019 and 2018 (in thousands): Three Months Ended March 31, 2019 2018 Accretable yield, beginning of period $ 449 $ 2,483 Accretion recognized in earnings (218 ) (599 ) Reduction due to payoff (33 ) — Accretable yield, end of period $ 198 $ 1,884

DEBT (Tables)

DEBT (Tables)	3 Months Ended
	Mar. 31, 2019
Debt Instrument [Line Items]
Schedule of Maturities for Outstanding Debt	The following is a schedule of maturities for the Company’s outstanding debt as of March 31, 2019 (in thousands): Secured Indebtedness Revolving Credit Facility (1) Term Loans Senior Notes Total April 1 through December 31, 2019 $ 2,584 $ — $ — $ — $ 2,584 2020 3,541 — 200,000 — 203,541 2021 18,446 620,000 — 500,000 1,138,446 2022 3,185 — 993,625 — 996,810 2023 3,282 — — 200,000 203,282 Thereafter 85,916 — — 600,000 685,916 Total Debt 116,954 620,000 1,193,625 1,300,000 3,230,579 Premium, net — — — 14,135 14,135 Deferred financing costs, net (1,766 ) — (6,241 ) (6,477 ) (14,484 ) Total Debt, Net $ 115,188 $ 620,000 $ 1,187,384 $ 1,307,658 $ 3,230,230 (1) Revolving Credit Facility is subject to two six -month extension options.
Secured Debt
Debt Instrument [Line Items]
Debt	The Company’s secured debt consists of the following (dollars in thousands): Interest Rate Type Principal Balance as of (1) Principal Balance as of (1) Weighted Average (2) Maturity Date Fixed Rate $ 116,954 $ 117,464 3.66 % December 2021 - (1) Principal balance does not include deferred financing costs, net of $ 1.8 million as of each of March 31, 2019 and December 31, 2018 . (2) Weighted average effective interest rate includes private mortgage insurance.
Senior Notes
Debt Instrument [Line Items]
Debt	The Company’s senior unsecured notes consist of the following (dollars in thousands): Principal Balance as of Title Maturity Date March 31, 2019 (1) December 31, 2018 (1) 5.5% senior unsecured notes due 2021 (“2021 Notes”) February 1, 2021 $ 500,000 $ 500,000 5.375% senior unsecured notes due 2023 (“2023 Notes”) June 1, 2023 200,000 200,000 5.125% senior unsecured notes due 2026 (“2026 Notes”) August 15, 2026 500,000 500,000 5.38% senior unsecured notes due 2027 (“2027 Notes”) May 17, 2027 100,000 100,000 $ 1,300,000 $ 1,300,000 (1) Principal balance does not include premium, net of $14.1 million and deferred financing costs, net of $6.5 million as of March 31, 2019 and does not include premium, net of $14.5 million and deferred financing costs, net of $7.1 million as of December 31, 2018 .

DERIVATIVE AND HEDGING INSTRU_2

DERIVATIVE AND HEDGING INSTRUMENTS (Tables)	3 Months Ended
	Mar. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Notional Amount of Derivatives Instruments	The following presents the notional amount of derivative instruments as of the dates indicated (in thousands): March 31, 2019 December 31, 2018 Derivatives designated as cash flow hedges: Denominated in U.S. Dollars (1) $ 1,100,000 $ 1,045,000 Denominated in Canadian Dollars $ 125,000 $ 125,000 Derivatives designated as net investment hedges: Denominated in Canadian Dollars $ 56,050 $ 55,401 Financial instrument designated as net investment hedge: Denominated in Canadian Dollars $ 125,000 $ 125,000 Derivatives not designated as net investment hedges: Denominated in Canadian Dollars $ 250 $ 899 (1) Balance includes forward starting interest rate swaps having an effective date of June 2019 that were entered into as of March 31, 2019 to hedge $255.0 million of anticipated fixed-rate debt issuance to occur sometime during 2019.
Derivative and Financial Instruments Designated as Hedging Instruments	The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at March 31, 2019 and December 31, 2018 (dollars in thousands): Count as of March 31, 2019 Fair Value Maturity Dates Type Designation March 31, 2019 December 31, 2018 Balance Sheet Location Assets: Interest rate swaps Cash flow 12 $ 18,057 $ 25,184 2020 - 2023 Accounts receivable, prepaid expenses and other assets, net Cross currency interest rate swaps Net investment 2 2,883 4,160 2025 Accounts receivable, prepaid expenses and other assets, net $ 20,940 $ 29,344 Liabilities: Forward starting interest rate swaps Cash flow 3 $ 11,926 $ 4,529 2029 Accounts payable and accrued liabilities CAD term loan Net investment 1 93,625 91,700 2022 Term loans, net $ 105,551 $ 96,229
Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Equity	The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the condensed consolidated statements of income and the condensed consolidated statements of equity for the three months ended March 31, 2019 and 2018 (in thousands): (Loss) Gain Recognized in Other Comprehensive (Loss) Income Three Months Ended March 31, 2019 2018 Income Statement Location Cash Flow Hedges: Interest rate products $ (11,611 ) $ 9,123 Interest expense Net Investment Hedges: Foreign currency products (1,234 ) 607 N/A CAD term loan (1,925 ) 2,675 N/A $ (14,770 ) $ 12,405 Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income Three Months Ended March 31, 2019 2018 Income Statement Location Cash Flow Hedges: Interest rate products $ 1,913 $ (50 ) Interest expense
Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives - Assets	The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of March 31, 2019 and December 31, 2018 (in thousands): As of March 31, 2019 Gross Amounts of Recognized Assets / Liabilities Gross Amounts Offset in the Balance Sheet Net Amounts of Assets / Liabilities presented in the Balance Sheet Gross Amounts Not Offset in the Balance Sheet Financial Instruments Cash Collateral Received Net Amount Offsetting Assets: Derivatives $ 20,940 $ — $ 20,940 $ (6,349 ) $ — $ 14,591 Offsetting Liabilities: Derivatives $ 11,926 $ — $ 11,926 $ (6,349 ) $ — $ 5,577 As of December 31, 2018 Gross Amounts of Recognized Assets / Liabilities Gross Amounts Offset in the Balance Sheet Net Amounts of Assets / Liabilities presented in the Balance Sheet Gross Amounts Not Offset in the Balance Sheet Financial Instruments Cash Collateral Received Net Amount Offsetting Assets: Derivatives $ 29,344 $ — $ 29,344 $ (2,069 ) $ — $ 27,275 Offsetting Liabilities: Derivatives $ 4,529 $ — $ 4,529 $ (2,069 ) $ — $ 2,460
Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives - Liabilities	The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of March 31, 2019 and December 31, 2018 (in thousands): As of March 31, 2019 Gross Amounts of Recognized Assets / Liabilities Gross Amounts Offset in the Balance Sheet Net Amounts of Assets / Liabilities presented in the Balance Sheet Gross Amounts Not Offset in the Balance Sheet Financial Instruments Cash Collateral Received Net Amount Offsetting Assets: Derivatives $ 20,940 $ — $ 20,940 $ (6,349 ) $ — $ 14,591 Offsetting Liabilities: Derivatives $ 11,926 $ — $ 11,926 $ (6,349 ) $ — $ 5,577 As of December 31, 2018 Gross Amounts of Recognized Assets / Liabilities Gross Amounts Offset in the Balance Sheet Net Amounts of Assets / Liabilities presented in the Balance Sheet Gross Amounts Not Offset in the Balance Sheet Financial Instruments Cash Collateral Received Net Amount Offsetting Assets: Derivatives $ 29,344 $ — $ 29,344 $ (2,069 ) $ — $ 27,275 Offsetting Liabilities: Derivatives $ 4,529 $ — $ 4,529 $ (2,069 ) $ — $ 2,460

FAIR VALUE DISCLOSURES (Tables)

FAIR VALUE DISCLOSURES (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Face Values, Carrying Amounts and Fair Values of Financial Instruments	The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of March 31, 2019 and December 31, 2018 whose carrying amounts do not approximate their fair value (in thousands): March 31, 2019 December 31, 2018 Face (1) Carrying Amount (2) Fair Value Face (1) Carrying (2) Fair Value Financial assets: Loans receivable $ 71,520 $ 65,789 $ 66,146 $ 96,492 $ 69,460 $ 65,797 Preferred equity investments 43,014 43,425 43,834 43,851 44,262 43,825 Financial liabilities: Senior Notes 1,300,000 1,307,658 1,301,575 1,300,000 1,307,394 1,270,877 Secured indebtedness 116,954 115,188 104,244 117,464 115,679 101,820 (1) Face value represents amounts contractually due under the terms of the respective agreements. (2) Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.
Fair Value of Financial Instruments	The Company determined the fair value of financial instruments as of March 31, 2019 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands): Fair Value Measurements Using Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Financial assets: Loans receivable $ 66,146 $ — $ — $ 66,146 Preferred equity investments 43,834 — — 43,834 Financial liabilities: Senior Notes 1,301,575 — 1,301,575 — Secured indebtedness 104,244 — — 104,244
Items Measured at Fair Value on a Recurring Basis	During the three months ended March 31, 2019 , the Company recorded the following amounts measured at fair value (in thousands): Fair Value Measurements Using Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Recurring Basis: Financial assets: Interest rate swap $ 18,057 $ — $ 18,057 $ — Cross currency swap 2,883 — 2,883 — Financial liabilities: Interest rate swap 11,926 — 11,926 —

EQUITY (Tables)

EQUITY (Tables)	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Cash Dividends on Common Stock Declared and Paid	The following table lists the cash dividends on common stock declared and paid by the Company during the three months ended March 31, 2019 : Declaration Date Record Date Amount Per Share Dividend Payable Date February 5, 2019 February 15, 2019 $ 0.45 February 28, 2019
Accumulated Other Comprehensive (Loss) Income	The following is a summary of the Company’s accumulated other comprehensive (loss) income (in thousands): March 31, 2019 December 31, 2018 Foreign currency translation loss $ (2,753 ) $ (2,193 ) Unrealized gains on cash flow hedges 1,006 14,494 Total accumulated other comprehensive (loss) income $ (1,747 ) $ 12,301

EARNINGS PER COMMON SHARE (Tabl

EARNINGS PER COMMON SHARE (Tables)	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table illustrates the computation of basic and diluted earnings per share for the three months ended March 31, 2019 and 2018 (in thousands, except share and per share amounts): Three Months Ended March 31, 2019 2018 Numerator Net (loss) income attributable to common stockholders $ (77,704 ) $ 59,910 Denominator Basic weighted average common shares and common equivalents 178,385,984 178,294,605 Dilutive restricted stock units — 221,783 Diluted weighted average common shares 178,385,984 178,516,388 Net (loss) income attributable to common stockholders, per: Basic common share $ (0.44 ) $ 0.34 Diluted common share $ (0.44 ) $ 0.34

SUMMARIZED CONDENSED CONSOLID_2

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2019
Summarized Condensed Consolidating Information [Abstract]
Condensed Consolidating Balance Sheet	CONDENSED CONSOLIDATING BALANCE SHEET March 31, 2019 (in thousands) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Assets Real estate investments, net of accumulated depreciation $ 306 $ — $ — $ 1,597,664 $ 3,839,384 $ — $ 5,437,354 Loans receivable and other investments, net (533 ) — — 49,730 60,017 — 109,214 Investment in unconsolidated joint venture — — — — 335,701 — 335,701 Cash and cash equivalents 14,770 — — 1,570 6,533 — 22,873 Restricted cash — — — 1,845 7,921 — 9,766 Assets held for sale — — — — 270,780 — 270,780 Lease intangible assets, net — — — 15,469 104,198 — 119,667 Accounts receivable, prepaid expenses and other assets, net 5,171 27,962 — 30,770 92,782 (6,895 ) 149,790 Intercompany 1,893,948 2,619,046 — — — (4,512,994 ) — Investment in subsidiaries 1,155,457 1,558,253 — 32,540 — (2,746,250 ) — Total assets $ 3,069,119 $ 4,205,261 $ — $ 1,729,588 $ 4,717,316 $ (7,266,139 ) $ 6,455,145 Liabilities Secured debt, net $ — $ — $ — $ — $ 115,188 $ — $ 115,188 Revolving credit facility — 620,000 — — — — 620,000 Term loans, net — 1,094,639 — 92,745 — — 1,187,384 Senior unsecured notes, net — 1,307,658 — — — — 1,307,658 Accounts payable and accrued liabilities 22,650 27,507 — 3,344 48,203 (6,895 ) 94,809 Lease intangible liabilities, net — — — — 79,328 — 79,328 Intercompany — — — 350,674 4,162,320 (4,512,994 ) — Total liabilities 22,650 3,049,804 — 446,763 4,405,039 (4,519,889 ) 3,404,367 Total Sabra Health Care REIT, Inc. stockholders’ equity 3,046,469 1,155,457 — 1,282,825 307,968 (2,746,250 ) 3,046,469 Noncontrolling interests — — — — 4,309 — 4,309 Total equity 3,046,469 1,155,457 — 1,282,825 312,277 (2,746,250 ) 3,050,778 Total liabilities and equity $ 3,069,119 $ 4,205,261 $ — $ 1,729,588 $ 4,717,316 $ (7,266,139 ) $ 6,455,145 (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes. CONDENSED CONSOLIDATING BALANCE SHEET December 31, 2018 (in thousands) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Assets Real estate investments, net of accumulated depreciation $ 317 $ — $ — $ 1,609,861 $ 4,243,367 $ — $ 5,853,545 Loans receivable and other investments, net (560 ) — — 50,534 63,748 — 113,722 Investment in unconsolidated joint venture — — — — 340,120 — 340,120 Cash and cash equivalents 40,835 — — 3,508 5,887 — 50,230 Restricted cash — — — 1,820 7,608 — 9,428 Lease intangible assets, net — — — 15,892 115,205 — 131,097 Accounts receivable, prepaid expenses and other assets, net 798 37,075 — 58,710 81,597 (11,019 ) 167,161 Intercompany 1,972,059 2,646,669 — — — (4,618,728 ) — Investment in subsidiaries 1,258,715 1,629,795 — 33,083 — (2,921,593 ) — Total assets $ 3,272,164 $ 4,313,539 $ — $ 1,773,408 $ 4,857,532 $ (7,551,340 ) $ 6,665,303 Liabilities Secured debt, net $ — $ — $ — $ — $ 115,679 $ — $ 115,679 Revolving credit facility — 624,000 — — — — 624,000 Term loans, net — 1,094,177 — 90,753 — — 1,184,930 Senior unsecured notes, net — 1,307,394 — — — — 1,307,394 Accounts payable and accrued liabilities 21,750 29,253 — 2,695 52,148 (11,019 ) 94,827 Lease intangible liabilities, net — — — — 83,726 — 83,726 Intercompany — — — 399,912 4,218,816 (4,618,728 ) — Total liabilities 21,750 3,054,824 — 493,360 4,470,369 (4,629,747 ) 3,410,556 Total Sabra Health Care REIT, Inc. stockholders’ equity 3,250,414 1,258,715 — 1,280,048 382,830 (2,921,593 ) 3,250,414 Noncontrolling interests — — — — 4,333 — 4,333 Total equity 3,250,414 1,258,715 — 1,280,048 387,163 (2,921,593 ) 3,254,747 Total liabilities and equity $ 3,272,164 $ 4,313,539 $ — $ 1,773,408 $ 4,857,532 $ (7,551,340 ) $ 6,665,303 (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.
Condensed Consolidating Statement of Income	CONDENSED CONSOLIDATING STATEMENT OF (LOSS) INCOME For the Three Months Ended March 31, 2019 (dollars in thousands, except per share amounts) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Revenues: Rental and related revenues $ — $ — $ — $ 32,125 $ 88,638 $ (4,376 ) $ 116,387 Interest and other income 29 96 — 1,231 2,065 (96 ) 3,325 Resident fees and services — — — — 17,061 — 17,061 Total revenues 29 96 — 33,356 107,764 (4,472 ) 136,773 Expenses: Depreciation and amortization 12 — — 12,888 32,049 — 44,949 Interest — 34,275 — 903 1,236 (96 ) 36,318 Triple-net portfolio operating expenses — — — 1,014 4,275 — 5,289 Senior Housing - Managed portfolio operating expenses — — — — 16,416 (4,376 ) 12,040 General and administrative 7,525 31 — 167 455 — 8,178 Merger and acquisition costs 6 — — — — — 6 (Recovery of) provision for doubtful accounts, straight-line rental income and loan losses (27 ) — — — 1,234 — 1,207 Impairment of real estate — — — — 103,134 — 103,134 Total expenses 7,516 34,306 — 14,972 158,799 (4,472 ) 211,121 Other (expense) income: Other (expense) income — (498 ) — 492 177 — 171 Net loss on sales of real estate — — — (375 ) (1,145 ) — (1,520 ) Total other (expense) income — (498 ) — 117 (968 ) — (1,349 ) (Loss) income in subsidiary (69,777 ) (35,068 ) — 1,668 — 103,177 — (Loss) income before loss from unconsolidated joint venture and income tax expense (77,264 ) (69,776 ) — 20,169 (52,003 ) 103,177 (75,697 ) Loss from unconsolidated joint venture — — — — (1,383 ) — (1,383 ) Income tax expense (440 ) (1 ) — (105 ) (66 ) — (612 ) Net (loss) income (77,704 ) (69,777 ) — 20,064 (53,452 ) 103,177 (77,692 ) Net income attributable to noncontrolling interests — — — — (12 ) — (12 ) Net (loss) income attributable to common stockholders $ (77,704 ) $ (69,777 ) $ — $ 20,064 $ (53,464 ) $ 103,177 $ (77,704 ) Net loss attributable to common stockholders, per: Basic common share $ (0.44 ) Diluted common share $ (0.44 ) Weighted-average number of common shares outstanding, basic 178,385,984 Weighted-average number of common shares outstanding, diluted 178,385,984 (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes. CONDENSED CONSOLIDATING STATEMENT OF INCOME For the Three Months Ended March 31, 2018 (dollars in thousands, except per share amounts) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Revenues: Rental and related revenues $ — $ — $ — $ 45,464 $ 103,024 $ (4,233 ) $ 144,255 Interest and other income 10 112 — 1,267 3,061 (112 ) 4,338 Resident fees and services — — — — 17,493 — 17,493 Total revenues 10 112 — 46,731 123,578 (4,345 ) 166,086 Expenses: Depreciation and amortization 222 — — 14,930 32,853 — 48,005 Interest — 32,566 — 790 2,574 (112 ) 35,818 Senior Housing - Managed portfolio operating expenses — — — — 16,357 (4,233 ) 12,124 General and administrative 5,822 14 — 431 1,600 — 7,867 Merger and acquisition costs 336 — — — (6 ) — 330 Provision for (recovery of) doubtful accounts, straight-line rental income and loan losses 2,181 — — (971 ) 3 — 1,213 Impairment of real estate — — — 532 — — 532 Total expenses 8,561 32,580 — 15,712 53,381 (4,345 ) 105,889 Other income (expense): Other income 1,977 201 — 410 232 — 2,820 Net loss on sales of real estate — — — (56 ) (416 ) — (472 ) Total other income (expense) 1,977 201 — 354 (184 ) — 2,348 Income in subsidiary 69,343 101,610 — 1,854 — (172,807 ) — Income before income from unconsolidated joint venture and income tax expense 62,769 69,343 — 33,227 70,013 (172,807 ) 62,545 Income from unconsolidated joint venture — — — — 446 — 446 Income tax expense (298 ) — — (53 ) (159 ) — (510 ) Net income 62,471 69,343 — 33,174 70,300 (172,807 ) 62,481 Net income attributable to noncontrolling interests — — — — (10 ) — (10 ) Net income attributable to Sabra Health Care REIT, Inc. 62,471 69,343 — 33,174 70,290 (172,807 ) 62,471 Preferred stock dividends (2,561 ) — — — — — (2,561 ) Net income attributable to common stockholders $ 59,910 $ 69,343 $ — $ 33,174 $ 70,290 $ (172,807 ) $ 59,910 Net income attributable to common stockholders, per: Basic common share $ 0.34 Diluted common share $ 0.34 Weighted-average number of common shares outstanding, basic 178,294,605 Weighted-average number of common shares outstanding, diluted 178,516,388 (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.
Condensed Consolidating Statement of Comprehensive (Loss) Income	CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE (LOSS) INCOME For the Three Months Ended March 31, 2019 (dollars in thousands) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Net (loss) income $ (77,704 ) $ (69,777 ) $ — $ 20,064 $ (53,452 ) $ 103,177 $ (77,692 ) Other comprehensive income (loss): Unrealized gain (loss), net of tax: Foreign currency translation (loss) gain — (1,437 ) — 678 199 — (560 ) Unrealized loss on cash flow hedges — (13,486 ) — (2 ) — — (13,488 ) Total other comprehensive (loss) income — (14,923 ) — 676 199 — (14,048 ) Comprehensive (loss) income (77,704 ) (84,700 ) — 20,740 (53,253 ) 103,177 (91,740 ) Comprehensive income attributable to noncontrolling interest — — — — (12 ) — (12 ) Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc. $ (77,704 ) $ (84,700 ) $ — $ 20,740 $ (53,265 ) $ 103,177 $ (91,752 ) (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes. CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME For the Three Months Ended March 31, 2018 (dollars in thousands) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Net income $ 62,471 $ 69,343 $ — $ 33,174 $ 70,300 $ (172,807 ) $ 62,481 Other comprehensive income (loss): Unrealized gain (loss), net of tax: Foreign currency translation gain (loss) — 841 — (928 ) (287 ) — (374 ) Unrealized gain (loss) on cash flow hedges — 9,903 — (5 ) — — 9,898 Total other comprehensive income (loss) — 10,744 — (933 ) (287 ) — 9,524 Comprehensive income 62,471 80,087 — 32,241 70,013 (172,807 ) 72,005 Comprehensive income attributable to noncontrolling interest — — — — (10 ) — (10 ) Comprehensive income attributable to Sabra Health Care REIT, Inc. $ 62,471 $ 80,087 $ — $ 32,241 $ 70,003 $ (172,807 ) $ 71,995 (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.
Condensed Consolidating Statement of Cash Flows	CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2019 (in thousands) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Net cash provided by (used in) operating activities $ 49,833 $ — $ — $ (379 ) $ 4,505 $ — $ 53,959 Cash flows from investing activities: Origination and fundings of loans receivable — — — (352 ) (2,424 ) — (2,776 ) Additions to real estate — — — (1,936 ) (3,136 ) — (5,072 ) Repayments of loans receivable — — — 61 5,190 — 5,251 Repayments of preferred equity investments — — — 2,087 — — 2,087 Net proceeds from the sales of real estate — — — 3,829 3,028 — 6,857 Distribution from subsidiaries 2,569 2,569 — — — (5,138 ) — Intercompany financing 4,116 8,122 — — — (12,238 ) — Net cash provided by investing activities 6,685 10,691 — 3,689 2,658 (17,376 ) 6,347 Cash flows from financing activities: Net repayments of revolving credit facility — (4,000 ) — — — — (4,000 ) Principal payments on secured debt — — — — (849 ) — (849 ) Payments of deferred financing costs — (6 ) — — — — (6 ) Distributions to noncontrolling interest — — — — (36 ) — (36 ) Issuance of common stock, net (2,323 ) — — — — — (2,323 ) Dividends paid on common stock (80,260 ) — — — — — (80,260 ) Distribution to parent — (2,569 ) — — (2,569 ) 5,138 — Intercompany financing — (4,116 ) — (5,331 ) (2,791 ) 12,238 — Net cash used in financing activities (82,583 ) (10,691 ) — (5,331 ) (6,245 ) 17,376 (87,474 ) Net (decrease) increase in cash, cash equivalents and restricted cash (26,065 ) — — (2,021 ) 918 — (27,168 ) Effect of foreign currency translation on cash, cash equivalents and restricted cash — — — 108 41 — 149 Cash, cash equivalents and restricted cash, beginning of period 40,835 — — 5,328 13,495 — 59,658 Cash, cash equivalents and restricted cash, end of period $ 14,770 $ — $ — $ 3,415 $ 14,454 $ — $ 32,639 (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes. CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2018 (in thousands) (unaudited) Combined Non-Guarantor Subsidiaries of 2026 Notes (6) Parent (1) Operating Partnership (2) Sabra Capital Corporation (3) Combined (4) Combined Non- (5) Elimination Consolidated Net cash provided by (used in) operating activities $ 97,936 $ — $ — $ (55 ) $ 3,766 $ — $ 101,647 Cash flows from investing activities: Acquisition of real estate — — — (172,001 ) — — (172,001 ) Origination and fundings of loans receivable — — — (1,027 ) (12,205 ) — (13,232 ) Origination and fundings of preferred equity investments — — — (928 ) — — (928 ) Additions to real estate (38 ) — — (3,496 ) (8,005 ) — (11,539 ) Repayments of loans receivable — — — 7,491 21,314 — 28,805 Repayments of preferred equity investments — — — 234 — — 234 Investment in unconsolidated JV — — — — (354,461 ) — (354,461 ) Net proceeds from the sales of real estate — — — — 6,743 — 6,743 Distribution from subsidiaries 2,557 2,557 — — — (5,114 ) — Intercompany financing (488,718 ) (458,712 ) — — — 947,430 — Net cash (used in) provided by investing activities (486,199 ) (456,155 ) — (169,727 ) (346,614 ) 942,316 (516,379 ) Cash flows from financing activities: Net repayments of revolving credit facility — (30,000 ) — — — — (30,000 ) Principal payments on secured debt — — — — (1,061 ) — (1,061 ) Payments of deferred financing costs — (6 ) — — — — (6 ) Distribution to noncontrolling interest — — — — (37 ) — (37 ) Issuance of common stock, net (499 ) — — — — — (499 ) Dividends paid on common and preferred stock (82,789 ) — — — — — (82,789 ) Distribution to parent — (2,557 ) — — (2,557 ) 5,114 — Intercompany financing — 488,718 — 134,797 323,915 (947,430 ) — Net cash (used in) provided by financing activities (83,288 ) 456,155 — 134,797 320,260 (942,316 ) (114,392 ) Net decrease in cash, cash equivalents and restricted cash (471,551 ) — — (34,985 ) (22,588 ) — (529,124 ) Effect of foreign currency translation on cash, cash equivalents and restricted cash — — — (72 ) (83 ) — (155 ) Cash, cash equivalents and restricted cash, beginning of period 511,670 — — 37,359 38,420 — 587,449 Cash, cash equivalents and restricted cash, end of period $ 40,119 $ — $ — $ 2,302 $ 15,749 $ — $ 58,170 (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes. (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes. (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes. (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes. (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes. (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Principles of Consolidation and Basis of Presentation (Details)	3 Months Ended
	Mar. 31, 2019variable_interest_entityInvestment
Variable Interest Entity [Line Items]
Number of investments in loans accounted for as real estate joint ventures | Investment	0
Primary Beneficiary
Variable Interest Entity [Line Items]
Number of VIEs	1
Skilled Nursing Transitional Care Facilities | Primary Beneficiary
Variable Interest Entity [Line Items]
Number of VIEs	1

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Investment in Unconsolidated Joint Venture (Details) $ in Thousands	Jan. 02, 2018USD ($)Propertydirector	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Schedule of Equity Method Investments [Line Items]
Investment in joint venture		$ 335,701	$ 340,120
Enlivant Joint Venture
Schedule of Equity Method Investments [Line Items]
Number of properties | Property	172
Enlivant Joint Venture
Schedule of Equity Method Investments [Line Items]
Cash contributed to acquire equity interests	$ 352,700
Equity interest in joint venture	49.00%
Outstanding indebtedness	$ 791,300
Net working capital	$ 22,900
Number of directors appointed by Sabra | director	3
Number of directors on board | director	7
Investment in joint venture		$ 335,700

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Investment in Direct Financing Lease (Details) - Skilled Nursing Transitional Care Facilities $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)Property
Lessor, Lease, Description [Line Items]
Net investment in direct financing lease	$ 23.5
Number of properties in direct financing lease | Property	1
Undiscounted rental payments	$ 5.2
Unguaranteed residual value	24.7
Unearned lease income	6.4
Lease income	0.6
Minimum lease payments contractually due under direct financing leases
Due in the remainder of 2019	1.7
Due in 2020	2.3
Due in 2021	$ 2.1

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recently Issued Accounting Update (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease liability	$ 10,000
Operating lease right-of-use asset	9,800
Variable lease revenue	4,200
Variable lease expense	$ 4,200
ASU 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease liability		$ 10,000
Operating lease right-of-use asset		10,000
Reduction to equity and accounts receivable, prepaid expenses and other assets, net, as of the date of adoption		32,502
Straight-line rental income receivables		17,500
Cash rent receivable		$ 15,000

RECENT REAL ESTATE ACQUISITIO_3

RECENT REAL ESTATE ACQUISITIONS - Narrative (Details) - Recent Real Estate Acquisitions $ in Millions	3 Months Ended
	Mar. 31, 2019Property	Mar. 31, 2018USD ($)Property
Business Acquisition [Line Items]
Number of acquired properties	0
Total revenues | $		$ 9.7
Net income attributable to common stockholders | $		$ 0.9
Tenant Origination and Absorption Costs
Business Acquisition [Line Items]
Weighted average amortization period of finite-lived intangible assets		13 years
Tenant Relationship
Business Acquisition [Line Items]
Weighted average amortization period of finite-lived intangible assets		23 years
Senior Housing - Managed
Business Acquisition [Line Items]
Number of acquired properties		11
Skilled Nursing/Transitional Care
Business Acquisition [Line Items]
Number of acquired properties		2
Senior Housing Facilities
Business Acquisition [Line Items]
Number of acquired properties		1

RECENT REAL ESTATE ACQUISITIO_4

RECENT REAL ESTATE ACQUISITIONS - Purchase Price Allocation for Recent Real Estate Acquisitions (Details) - Recent Real Estate Acquisitions $ in Thousands	Mar. 31, 2018USD ($)
Business Acquisition [Line Items]
Land	$ 20,552
Building and improvements	150,523
Total consideration	172,006
Tenant origination and absorption costs intangible assets
Business Acquisition [Line Items]
Tenant intangible assets	722
Tenant relationship intangible assets
Business Acquisition [Line Items]
Tenant intangible assets	$ 209

REAL ESTATE PROPERTIES HELD F_3

REAL ESTATE PROPERTIES HELD FOR INVESTMENT - Real Estate Properties Held for Investment (Details) $ in Thousands	Mar. 31, 2019USD ($)Bedfacility	Dec. 31, 2018USD ($)Bedfacility
Real Estate Properties [Line Items]
Building and improvements	$ 5,044,382	$ 5,388,102
Furniture and equipment	221,123	237,145
Land improvements	1,317	1,254
Land	596,494	629,382
Total Real Estate at Cost	5,863,316	6,255,883
Accumulated Depreciation	(425,962)	(402,338)
Total Real Estate Investments, Net	$ 5,437,354	$ 5,853,545
Operating Segments
Real Estate Properties [Line Items]
Number of Properties | facility	437	470
Number of Beds/Units | Bed	43,884	47,648
Total Real Estate at Cost	$ 5,862,682	$ 6,255,249
Accumulated Depreciation	(425,634)	(402,021)
Total Real Estate Investments, Net	5,437,048	5,853,228
Corporate Level
Real Estate Properties [Line Items]
Total Real Estate at Cost	634	634
Accumulated Depreciation	(328)	(317)
Total Real Estate Investments, Net	$ 306	$ 317
Skilled Nursing/Transitional Care | Operating Segments
Real Estate Properties [Line Items]
Number of Properties | facility	304	335
Number of Beds/Units | Bed	34,049	37,628
Total Real Estate at Cost	$ 3,716,115	$ 4,094,484
Accumulated Depreciation	(234,633)	(224,942)
Total Real Estate Investments, Net	$ 3,481,482	$ 3,869,542
Senior Housing - Leased | Operating Segments
Real Estate Properties [Line Items]
Number of Properties | facility	88	90
Number of Beds/Units | Bed	7,147	7,332
Total Real Estate at Cost	$ 1,220,158	$ 1,237,790
Accumulated Depreciation	(133,570)	(125,902)
Total Real Estate Investments, Net	$ 1,086,588	$ 1,111,888
Senior Housing - Managed | Operating Segments
Real Estate Properties [Line Items]
Number of Properties | facility	23	23
Number of Beds/Units | Bed	1,603	1,603
Total Real Estate at Cost	$ 305,173	$ 301,739
Accumulated Depreciation	(22,037)	(19,537)
Total Real Estate Investments, Net	$ 283,136	$ 282,202
Specialty Hospitals and Other | Operating Segments
Real Estate Properties [Line Items]
Number of Properties | facility	22	22
Number of Beds/Units | Bed	1,085	1,085
Total Real Estate at Cost	$ 621,236	$ 621,236
Accumulated Depreciation	(35,394)	(31,640)
Total Real Estate Investments, Net	$ 585,842	$ 589,596

REAL ESTATE PROPERTIES HELD F_4

REAL ESTATE PROPERTIES HELD FOR INVESTMENT - Operating Leases (Details) $ in Thousands	Apr. 01, 2019USD ($)facility	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)facility	Mar. 31, 2018USD ($)	Jan. 31, 2019facility	Dec. 31, 2018USD ($)	Dec. 19, 2018facility
Real Estate Properties [Line Items]
Weighted-average remaining term of operating leases			9 years
Security deposit liability			$ 12,600			$ 12,400
Letters of credit deposited			95,000			98,000
Tenant deposits for future real estate taxes, insurance expenditures, and tenant improvements			14,200			$ 17,500
Portion of settlement applied to post-petition rent			5,700
Impairment of real estate			$ 103,134	$ 532
Forecast
Real Estate Properties [Line Items]
Portion of settlement applied to post-petition rent		$ 500
Minimum
Real Estate Properties [Line Items]
Operating lease expiration term			1 year
Maximum
Real Estate Properties [Line Items]
Operating lease expiration term			15 years
Holiday
Real Estate Properties [Line Items]
Number of properties subject to the master lease | facility							21
Holiday | Subsequent Event
Real Estate Properties [Line Items]
Cash consideration received	$ 57,200
Senior Care Centers
Real Estate Properties [Line Items]
Settlement amount			$ 9,500
Senior Care Centers Sale Facilities
Real Estate Properties [Line Items]
Impairment of real estate			92,200
Impairment of real estate related to indemnity			$ 10,200
Senior Care Centers Sale Facilities | Senior Care Centers | Subsequent Event
Real Estate Properties [Line Items]
Aggregate sale price of facility	$ 282,500
Number of facilities sold | facility	28
Settlement payments received	$ 5,000
Settlement payments receivable	$ 4,500
Senior Housing - Managed Communities | Operating Segments
Real Estate Properties [Line Items]
Number of properties | facility			23
Skilled Nursing Transitional Care Facilities
Real Estate Properties [Line Items]
Number of facilities expected to be sold | facility			28
Impairment of real estate			$ 10,900
Skilled Nursing Transitional Care Facilities | Senior Care Centers Sale Facilities
Real Estate Properties [Line Items]
Number of facilities expected to be sold | facility					26
Skilled Nursing Transitional Care Facilities | Senior Care Centers Sale Facilities | Subsequent Event
Real Estate Properties [Line Items]
Number of properties retained | facility	10
Number of properties expected to re-tenant to a current operator | facility	7
Number of properties expected to be sold | facility	3
Senior Housing Facilities
Real Estate Properties [Line Items]
Number of facilities expected to be sold | facility			2
Senior Housing Facilities | Senior Care Centers Sale Facilities
Real Estate Properties [Line Items]
Number of facilities expected to be sold | facility					2

REAL ESTATE PROPERTIES HELD F_5

REAL ESTATE PROPERTIES HELD FOR INVESTMENT - Future Minimum Rental Payments Receivable for Properties Held for Investment Under Non-Cancelable Operating Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases:
2019	$ 351,250
2020	456,660
2021	452,218
2022	454,086
2023	437,112
Thereafter	2,440,245
Total	$ 4,591,571
Future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases:
2019		$ 465,766
2020		456,207
2021		452,346
2022		454,216
2023		437,277
Thereafter		2,407,064
Total		$ 4,672,876

REAL ESTATE PROPERTIES HELD F_6

REAL ESTATE PROPERTIES HELD FOR INVESTMENT - Senior Housing - Managed Communities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Real Estate [Line Items]
Resident fees and services	$ 17,061	$ 17,493
Ancillary Services
Real Estate [Line Items]
Resident fees and services	$ 100	$ 100

IMPAIRMENT OF REAL ESTATE, AS_2

IMPAIRMENT OF REAL ESTATE, ASSETS HELD FOR SALE AND DISPOSITIONS (Details) $ in Thousands	Apr. 01, 2019USD ($)facility	Mar. 31, 2019USD ($)facility	Mar. 31, 2018USD ($)facility	Jan. 31, 2019facility	Dec. 31, 2018USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Real estate impairment		$ 103,134	$ 532
Assets held for sale, net		270,780			$ 0
Skilled Nursing Transitional Care Facilities and Senior Housing Facilities | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities sold | facility	29
Aggregate sale price of facility	$ 282,600
Skilled Nursing Transitional Care Facilities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Real estate impairment		$ 10,900
Number of real estate properties impaired | facility		4
Number of facilities expected to be sold | facility		28
Senior Housing Facilities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities expected to be sold | facility		2
Senior Housing Facilities | Dispositions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities sold with related impairment | facility			1
Senior Care Centers Sale Facilities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Real estate impairment		$ 92,200
Senior Care Centers Sale Facilities | Skilled Nursing Transitional Care Facilities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities expected to be sold | facility				26
Senior Care Centers Sale Facilities | Skilled Nursing Transitional Care Facilities | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties expected to be sold | facility	3
Senior Care Centers Sale Facilities | Senior Housing Facilities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities expected to be sold | facility				2
Senior Care Centers Sale Facilities | Senior Care Centers | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities sold | facility	28
Aggregate sale price of facility	$ 282,500
2019 Dispositions | Skilled Nursing Transitional Care Facilities | Dispositions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities sold | facility		3
Aggregate sale price of facility		$ 6,900
Carrying value of assets and liabilities of facility		8,400
Net loss on sale		1,500
Net income from facilities		$ 500	$ 17
2018 Dispositions | Skilled Nursing Transitional Care Facilities | Dispositions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities sold | facility			1
Aggregate sale price of facility			$ 6,800
Carrying value of assets and liabilities of facility			7,200
Net loss on sale			400
Net income from facilities			100
Selling expenses			$ 100

LOANS RECEIVABLE AND OTHER IN_3

LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details) $ in Thousands	Mar. 31, 2019USD ($)loan	Dec. 31, 2018USD ($)
Loans Receivable:
Quantity | loan	20
Principal balance	$ 71,520	$ 96,492
Book Value	$ 67,556	70,718
Weighted Average Contractual Interest Rate / Rate of Return	7.90%
Weighted Average Annualized Effective Interest Rate / Rate of Return	8.40%
Loan loss reserve	$ (1,767)	(1,258)
Loans receivable, net amount	$ 65,789	69,460
Other Investments:
Quantity | loan	9
Principal Balance	$ 43,014	43,851
Book Value	$ 43,425	44,262
Weighted Average Contractual Interest Rate / Rate of Return	12.00%
Weighted Average Annualized Effective Interest Rate / Rate of Return	12.00%
Total Quantity | loan	29
Total Principal Balance	$ 114,534
Total Book Value	$ 109,214	113,722
Total Weighted Average Contractual Interest Rate / Rate of Return	9.40%
Total Weighted Average Annualized Effective Interest Rate / Rate of Return	9.80%
Mortgage
Loans Receivable:
Quantity | loan	1
Principal balance	$ 19,000
Book Value	$ 19,000	18,577
Weighted Average Contractual Interest Rate / Rate of Return	10.00%
Weighted Average Annualized Effective Interest Rate / Rate of Return	10.00%
Construction
Loans Receivable:
Quantity | loan	2
Principal balance	$ 4,887
Book Value	$ 4,945	4,629
Weighted Average Contractual Interest Rate / Rate of Return	8.00%
Weighted Average Annualized Effective Interest Rate / Rate of Return	7.70%
Mezzanine
Loans Receivable:
Quantity | loan	0
Principal balance	$ 0
Book Value	$ 0	2,188
Other
Loans Receivable:
Quantity | loan	17
Principal balance	$ 47,633
Book Value	$ 43,611	$ 45,324
Weighted Average Contractual Interest Rate / Rate of Return	7.10%
Weighted Average Annualized Effective Interest Rate / Rate of Return	7.70%

LOANS RECEIVABLE AND OTHER IN_4

LOANS RECEIVABLE AND OTHER INVESTMENTS - Narrative (Details)	3 Months Ended
	Mar. 31, 2019USD ($)loan	Mar. 31, 2018USD ($)	Dec. 31, 2018USD ($)loan
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loans receivable investments | loan	20
Principal balance	$ 71,520,000		$ 96,492,000
Loan loss reserve	$ 1,767,000		1,258,000
Number of loans receivable considered to be impaired | loan	1
Principal balance of impaired loan receivable	$ 4,300,000		$ 1,300,000
Number of loans more than 90 days past due still accruing interest | loan			1
Book value of lonas more than 90 days past due and still accruing interest			$ 4,300,000
Nonperforming Financial Instruments
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loans receivable investments | loan			1
Number of loans receivable on nonaccrual status | loan	3		2
Book value of loans receivable on nonaccrual status	$ 4,300,000		$ 1,300,000
Specific Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan loss reserve in period	1,200,000	$ 0
Loan loss reserve	1,200,000		700,000
Portfolio-Based Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Increase (decrease) in portfolio-based loan loss reserve	(27,000)	$ 100,000
Loan loss reserve	$ 500,000		$ 600,000
Receivables Acquired with Deteriorated Credit Quality
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loans receivable investments | loan	6		7
Principal balance	$ 3,400,000		$ 27,700,000
Book value of loans receivable	$ 1,800,000		$ 4,200,000
Number of loans repaid | loan	1

LOANS RECEIVABLE AND OTHER IN_5

LOANS RECEIVABLE AND OTHER INVESTMENTS - Changes in the Accretable Yield (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Certain Loans Acquired in Transfer Not Accounted for as Debt Securities, Accretable Yield Movement Schedule [Roll Forward]
Accretable yield, beginning of period	$ 449	$ 2,483
Accretion recognized in earnings	(218)	(599)
Reduction due to payoff	(33)	0
Accretable yield, end of period	$ 198	$ 1,884

DEBT - Secured Debt (Details)

DEBT - Secured Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Deferred financing costs, net	$ 14,484
Secured Debt
Debt Instrument [Line Items]
Deferred financing costs, net	1,766	$ 1,800
Secured Debt | Fixed Rate
Debt Instrument [Line Items]
Fixed rate, principal amount	$ 116,954	$ 117,464
Weighted average effective interest rate	3.66%

DEBT - Senior Unsecured Notes (

DEBT - Senior Unsecured Notes (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Premium, net	$ 14,135,000
Deferred financing costs	$ 14,484,000
5.5% Senior Unsecured Notes due 2021
Debt Instrument [Line Items]
Interest rate	5.50%
5.375% Senior Unsecured Notes due 2023
Debt Instrument [Line Items]
Interest rate	5.375%
5.125% Senior Unsecured Notes due 2026
Debt Instrument [Line Items]
Interest rate	5.125%
5.38% Senior Unsecured Notes due 2027
Debt Instrument [Line Items]
Interest rate	5.38%
Senior Notes
Debt Instrument [Line Items]
Principal balance	$ 1,300,000,000	$ 1,300,000,000
Premium, net	14,135,000	14,500,000
Deferred financing costs	6,477,000	7,100,000
Senior Notes | 5.5% Senior Unsecured Notes due 2021
Debt Instrument [Line Items]
Principal balance	$ 500,000,000	500,000,000
Interest rate	5.50%
Senior Notes | 5.375% Senior Unsecured Notes due 2023
Debt Instrument [Line Items]
Principal balance	$ 200,000,000	200,000,000
Interest rate	5.375%
Senior Notes | 5.125% Senior Unsecured Notes due 2026
Debt Instrument [Line Items]
Principal balance	$ 500,000,000	500,000,000
Interest rate	5.125%
Senior Notes | 5.38% Senior Unsecured Notes due 2027
Debt Instrument [Line Items]
Principal balance	$ 100,000,000	$ 100,000,000
Interest rate	5.38%

DEBT - Narrative (Details)

DEBT - Narrative (Details)	Aug. 17, 2017USD ($)extension_option	Mar. 31, 2019USD ($)instrument	Mar. 31, 2018USD ($)	Dec. 31, 2018USD ($)	Aug. 17, 2017CAD ($)extension_option	Aug. 10, 2016USD ($)agreement	Aug. 10, 2016CAD ($)agreement	Jun. 10, 2015CAD ($)
Debt Instrument [Line Items]
Amount outstanding under credit facility		$ 620,000,000		$ 624,000,000
Interest expense		36,318,000	$ 35,818,000
Non-cash interest expense		2,600,000	$ 2,500,000
Accrued interest		$ 15,600,000		$ 24,000,000
Care Capital Properties | Interest Rate Swap
Debt Instrument [Line Items]
Fixed interest rate under swap		1.31%
Number of derivative agreements | instrument		8
5.5% Senior Unsecured Notes due 2021
Debt Instrument [Line Items]
Interest rate		5.50%
5.375% Senior Unsecured Notes due 2023
Debt Instrument [Line Items]
Interest rate		5.375%
5.125% Senior Unsecured Notes due 2026
Debt Instrument [Line Items]
Interest rate		5.125%
5.38% Senior Unsecured Notes due 2027
Debt Instrument [Line Items]
Interest rate		5.38%
Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing capacity	$ 1,000,000,000
Borrowing capacity in certain foreign currencies (up to)	$ 175,000,000
Number of extension options | extension_option	2				2
Extension period	6 months
Interest rate		3.74%
Credit Agreement | Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Annum percent unused borrowing fee	0.125%
Credit Agreement | Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Annum percent unused borrowing fee	0.30%
Credit Agreement | Revolving Credit Facility | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate		0.50%
Credit Agreement | Revolving Credit Facility | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate		1.00%
Credit Agreement | Revolving Credit Facility | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.00%
Credit Agreement | Revolving Credit Facility | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	0.65%
Credit Agreement | Revolving Credit Facility | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.875%
Credit Agreement | Revolving Credit Facility | LIBOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.65%
Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Borrowing capacity	$ 2,500,000,000
U.S. Dollar Term Loan
Debt Instrument [Line Items]
Face amount of debt						$ 245,000,000
U.S. Dollar Term Loan | Interest Rate Swap
Debt Instrument [Line Items]
Fixed interest rate under swap						0.90%	0.90%
Number of derivative agreements | agreement						2	2
U.S. Dollar Term Loan | Care Capital Properties
Debt Instrument [Line Items]
Face amount of debt		$ 600,000,000
U.S. Dollar Term Loan | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.00%
U.S. Dollar Term Loan | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	0.90%
U.S. Dollar Term Loan | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.90%
U.S. Dollar Term Loan | LIBOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.90%
U.S. Dollar Term Loan | CDOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.90%
U.S. Dollar Term Loan | CDOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.90%
U.S. Dollar Term Loan | Redemption Period One
Debt Instrument [Line Items]
Face amount of debt	$ 1,100,000,000
U.S. Dollar Term Loan | Redemption Period Two
Debt Instrument [Line Items]
Face amount of debt	$ 200,000,000
Canadian Term Loan
Debt Instrument [Line Items]
Face amount of debt					$ 125,000,000		$ 35,000,000
Canadian Term Loan | Interest Rate Swap
Debt Instrument [Line Items]
Fixed interest rate under swap						0.93%	0.93%
Number of derivative agreements | agreement						1	1
Revolving Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Amount outstanding under credit facility		620,000,000
Available borrowing capacity		$ 380,000,000
Prior Canadian Term Loan
Debt Instrument [Line Items]
Face amount of debt								$ 90,000,000
Fixed interest rate under swap								1.59%

DEBT - Schedule of Maturities f

DEBT - Schedule of Maturities for Outstanding Debt (Details) $ in Thousands	Aug. 17, 2017extension_option	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Debt Instrument [Line Items]
April 1 through December 31, 2019		$ 2,584
2020		203,541
2021		1,138,446
2022		996,810
2023		203,282
Thereafter		685,916
Total Debt		3,230,579
Premium, net		14,135
Deferred financing costs, net		(14,484)
Total Debt, Net		3,230,230
Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Number of extension options | extension_option	2
Extension period	6 months
Secured Indebtedness
Debt Instrument [Line Items]
April 1 through December 31, 2019		2,584
2020		3,541
2021		18,446
2022		3,185
2023		3,282
Thereafter		85,916
Total Debt		116,954
Premium, net		0
Deferred financing costs, net		(1,766)	$ (1,800)
Total Debt, Net		115,188
Revolving Credit Facility
Debt Instrument [Line Items]
April 1 through December 31, 2019		0
2020		0
2021		620,000
2022		0
2023		0
Thereafter		0
Total Debt		620,000
Premium, net		0
Deferred financing costs, net		0
Total Debt, Net		620,000
Term Loans
Debt Instrument [Line Items]
April 1 through December 31, 2019		0
2020		200,000
2021		0
2022		993,625
2023		0
Thereafter		0
Total Debt		1,193,625
Premium, net		0
Deferred financing costs, net		(6,241)
Total Debt, Net		1,187,384
Senior Notes
Debt Instrument [Line Items]
April 1 through December 31, 2019		0
2020		0
2021		500,000
2022		0
2023		200,000
Thereafter		600,000
Total Debt		1,300,000
Premium, net		14,135	14,500
Deferred financing costs, net		(6,477)	$ (7,100)
Total Debt, Net		$ 1,307,658

DERIVATIVE AND HEDGING INSTRU_3

DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details)	3 Months Ended
	Mar. 31, 2019USD ($)derivative	Mar. 31, 2018USD ($)	Dec. 31, 2018USD ($)
Derivative [Line Items]
Interest expense	$ 36,318,000	$ 35,818,000
Fair value of derivatives in a net liability position	11,926,000		$ 4,529,000
Credit Risk
Derivative [Line Items]
Fair value of derivatives in a net liability position	5,300,000
Termination value	5,300,000
Cash Flow Hedges | Interest Rate Swap
Derivative [Line Items]
Ineffectiveness on cash flow hedges	0
Ineffectiveness on cash flow hedges		$ 0
Designated as Hedging Instrument
Derivative [Line Items]
Fair value of derivatives in a net liability position	105,551,000		$ 96,229,000
Designated as Hedging Instrument | Cash Flow Hedges
Derivative [Line Items]
Gains included in accumulated other comprehensive loss which are expected to be reclassified into earnings in the next 12 months	$ 6,700,000
Not Designated as Hedging Instrument | Cross Currency Interest Rate Swaps
Derivative [Line Items]
Number of derivative instruments held | derivative	1
Fair value of derivative asset	$ 13,000
Other expense related to derivatives	$ 6,000

DERIVATIVE AND HEDGING INSTRU_4

DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amount of Derivatives Instruments (Details) $ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2019CAD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2018CAD ($)
Cross Currency Interest Rate Swaps | Designated as Hedging Instrument | Cash Flow Hedges
Derivative [Line Items]
Notional amount		$ 1,100,000	$ 125,000	$ 1,045,000	$ 125,000
Cross Currency Interest Rate Swaps | Designated as Hedging Instrument | Net Investment Hedges
Derivative [Line Items]
Notional amount			56,050		55,401
Notional amount			125,000		125,000
Cross Currency Interest Rate Swaps | Not Designated as Hedging Instrument | Net Investment Hedges
Derivative [Line Items]
Notional amount			$ 250		$ 899
Forecast
Derivative [Line Items]
Fixed-rate debt issuance	$ 255,000

DERIVATIVE AND HEDGING INSTRU_5

DERIVATIVE AND HEDGING INSTRUMENTS - Derivative and Financial Instruments Designated as Hedging Instruments (Details) $ in Thousands	Mar. 31, 2019USD ($)instrument	Dec. 31, 2018USD ($)
Assets:
Fair Value	$ 20,940	$ 29,344
Liabilities:
Fair Value	11,926	4,529
Designated as Hedging Instrument
Assets:
Fair Value	20,940	29,344
Liabilities:
Fair Value	$ 105,551	96,229
Designated as Hedging Instrument | Interest rate swaps | Cash flow | Accounts receivable, prepaid expenses and other assets, net
Assets:
Count | instrument	12
Fair Value	$ 18,057	25,184
Designated as Hedging Instrument | Interest rate swaps | Cash flow | Accounts payable and accrued liabilities
Liabilities:
Count | instrument	3
Fair Value	$ 11,926	4,529
Designated as Hedging Instrument | Cross currency interest rate swaps | Net investment | Accounts receivable, prepaid expenses and other assets, net
Assets:
Count | instrument	2
Fair Value	$ 2,883	4,160
Designated as Hedging Instrument | CAD term loan | Net investment | Term loans, net
Liabilities:
Count | instrument	1
Fair Value	$ 93,625	$ 91,700

DERIVATIVE AND HEDGING INSTRU_6

DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Equity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Derivative Instruments, Gain (Loss) [Line Items]
(Loss) gain recognized in other comprehensive (loss) income, cash flow hedges	$ (13,488)	$ 9,898
(Loss) gain in other comprehensive (loss) income, cash flow hedges and net investment hedges	(14,770)	12,405
Interest rate products
Derivative Instruments, Gain (Loss) [Line Items]
(Loss) gain recognized in other comprehensive (loss) income, cash flow hedges	(11,611)	9,123
Interest rate products | Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) reclassified from accumulated other comprehensive income into income, cash flow hedges	1,913	(50)
Foreign currency products
Derivative Instruments, Gain (Loss) [Line Items]
(Loss) gain recognized in other comprehensive (loss) income, net investment hedges	(1,234)	607
CAD term loan
Derivative Instruments, Gain (Loss) [Line Items]
(Loss) gain recognized in other comprehensive (loss) income, net investment hedges	$ (1,925)	$ 2,675

DERIVATIVE AND HEDGING INSTRU_7

DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Offsetting Assets:
Gross amounts of recognized assets	$ 20,940	$ 29,344
Gross amounts offset in the balance sheet, assets	0	0
Net amounts of assets presented in the balance sheet	20,940	29,344
Financial instruments, assets	(6,349)	(2,069)
Cash collateral received, assets	0	0
Net amount, assets	14,591	27,275
Offsetting Liabilities:
Gross amounts of recognized liabilities	11,926	4,529
Gross amounts offset in the balance sheet, liabilities	0	0
Liabilities presented in the balance sheet	11,926	4,529
Financial instruments, liabilities	(6,349)	(2,069)
Cash collateral received, liabilities	0	0
Net amount, liabilities	$ 5,577	$ 2,460

FAIR VALUE DISCLOSURES - Face V

FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Financial assets:
Loans receivable	$ 71,520	$ 96,492
Preferred equity investments	43,014	43,851
Senior Notes
Financial liabilities:
Financial liabilities	1,300,000	1,300,000
Secured Indebtedness
Financial liabilities:
Financial liabilities	116,954	117,464
Carrying Amount
Financial assets:
Loans receivable	65,789	69,460
Preferred equity investments	43,425	44,262
Carrying Amount | Senior Notes
Financial liabilities:
Financial liabilities	1,307,658	1,307,394
Carrying Amount | Secured Indebtedness
Financial liabilities:
Financial liabilities	115,188	115,679
Fair Value
Financial assets:
Loans receivable	66,146	65,797
Preferred equity investments	43,834	43,825
Fair Value | Senior Notes
Financial liabilities:
Financial liabilities	1,301,575	1,270,877
Fair Value | Secured Indebtedness
Financial liabilities:
Financial liabilities	$ 104,244	$ 101,820

FAIR VALUE DISCLOSURES - Fair V

FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	$ 66,146	$ 65,797
Preferred equity investments	43,834	43,825
Total | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,301,575	1,270,877
Total | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	104,244	$ 101,820
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	0
Preferred equity investments	0
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	0
Preferred equity investments	0
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2) | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,301,575
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2) | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	66,146
Preferred equity investments	43,834
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3) | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3) | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	104,244
Measured on a Recurring Basis | Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	66,146
Preferred equity investments	43,834
Measured on a Recurring Basis | Total | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,301,575
Measured on a Recurring Basis | Total | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	$ 104,244

FAIR VALUE DISCLOSURES - Items

FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	$ 20,940	$ 29,344
Financial liabilities	11,926	$ 4,529
Measured on a Recurring Basis | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	11,926
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Financial liabilities	0
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2) | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	18,057
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2) | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	2,883
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3) | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Financial liabilities	0
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3) | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Measured on a Recurring Basis | Total | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	18,057
Financial liabilities	11,926
Measured on a Recurring Basis | Total | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	$ 2,883

EQUITY - Preferred Stock (Detai

EQUITY - Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Millions	Jun. 01, 2018	Mar. 21, 2013
Class of Stock [Line Items]
Shares of preferred stock issued (in shares)		5,750,000
Preferred stock dividend rate		7.125%
Price per share of preferred stock (in dollars per share)		$ 25
Redemption price (in dollars per share)	$ 25
Accrued and unpaid dividends (in dollars per share)	0.4453125
Total redemption price (in dollars per share)	$ 25.4453125
Redemption charge related to original issuance costs	$ 5.5
Preferred Stock
Class of Stock [Line Items]
Shares of preferred stock redeemed (in shares)	5,750,000

EQUITY - Common Stock (Details)

EQUITY - Common Stock (Details) - USD ($)	Feb. 25, 2019	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Tax withholding obligations incurred on behalf of employees		$ 1,300,000	$ 200,000
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued upon vesting (in shares)		113,071
ATM Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate gross proceeds possible from sales of common stock under equity distribution agreement (up to)	$ 500,000,000
Commission rate (up to)	1.50%
Shares sold under the ATM Program (in shares)		0
Amount available under ATM Program		$ 500,000,000

EQUITY - Cash Dividends on Comm

EQUITY - Cash Dividends on Common Stock Declared and Paid (Details) - $ / shares	Feb. 05, 2019	Mar. 31, 2019	Mar. 31, 2018
Equity [Abstract]
Common dividends (in dollars per share)	$ 0.45	$ 0.45	$ 0.45

EQUITY - Accumulated Other Comp

EQUITY - Accumulated Other Comprehensive (Loss) Income (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	$ 3,050,778	$ 3,254,747	$ 3,426,566	$ 3,437,249
Total accumulated other comprehensive (loss) income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	(1,747)	12,301	$ 20,813	$ 11,289
Foreign currency translation loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	(2,753)	(2,193)
Unrealized gains on cash flow hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	$ 1,006	$ 14,494

EARNINGS PER COMMON SHARE - Com

EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Numerator
Net (loss) income attributable to common stockholders	$ (77,704)	$ 59,910
Denominator
Basic weighted average common shares and common equivalents (in shares)	178,385,984	178,294,605
Dilutive restricted stock units (in shares)	0	221,783
Diluted weighted average common shares (in shares)	178,385,984	178,516,388
Net (loss) income attributable to common stockholders, per:
Basic common share (in dollars per share)	$ (0.44)	$ 0.34
Diluted common share (in dollars per share)	$ (0.44)	$ 0.34

EARNINGS PER COMMON SHARE - Nar

EARNINGS PER COMMON SHARE - Narrative (Details) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in computation of diluted earnings per share (in shares)	3,100	21,400
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in computation of diluted earnings per share (in shares)	0	0

SUMMARIZED CONDENSED CONSOLID_3

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION - Condensed Consolidating Balance Sheet (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Assets
Real estate investments, net of accumulated depreciation	$ 5,437,354	$ 5,853,545
Loans receivable and other investments, net	109,214	113,722
Investment in unconsolidated joint venture	335,701	340,120
Cash and cash equivalents	22,873	50,230
Restricted cash	9,766	9,428
Assets held for sale, net	270,780	0
Lease intangible assets, net	119,667	131,097
Accounts receivable, prepaid expenses and other assets, net	149,790	167,161
Intercompany	0	0
Investment in subsidiaries	0	0
Total assets	6,455,145	6,665,303
Liabilities
Secured debt, net	115,188	115,679
Revolving credit facility	620,000	624,000
Term loans, net	1,187,384	1,184,930
Senior unsecured notes, net	1,307,658	1,307,394
Accounts payable and accrued liabilities	94,809	94,827
Lease intangible liabilities, net	79,328	83,726
Intercompany	0	0
Total liabilities	3,404,367	3,410,556
Total Sabra Health Care REIT, Inc. stockholders’ equity	3,046,469	3,250,414
Noncontrolling interests	4,309	4,333
Total equity	3,050,778	3,254,747	$ 3,426,566	$ 3,437,249
Total liabilities and equity	6,455,145	6,665,303
Elimination
Assets
Real estate investments, net of accumulated depreciation	0	0
Loans receivable and other investments, net	0	0
Investment in unconsolidated joint venture	0	0
Cash and cash equivalents	0	0
Restricted cash	0	0
Assets held for sale, net	0
Lease intangible assets, net	0	0
Accounts receivable, prepaid expenses and other assets, net	(6,895)	(11,019)
Intercompany	(4,512,994)	(4,618,728)
Investment in subsidiaries	(2,746,250)	(2,921,593)
Total assets	(7,266,139)	(7,551,340)
Liabilities
Secured debt, net	0	0
Revolving credit facility	0	0
Term loans, net	0	0
Senior unsecured notes, net	0	0
Accounts payable and accrued liabilities	(6,895)	(11,019)
Lease intangible liabilities, net	0	0
Intercompany	(4,512,994)	(4,618,728)
Total liabilities	(4,519,889)	(4,629,747)
Total Sabra Health Care REIT, Inc. stockholders’ equity	(2,746,250)	(2,921,593)
Noncontrolling interests	0	0
Total equity	(2,746,250)	(2,921,593)
Total liabilities and equity	(7,266,139)	(7,551,340)
Parent Company | Reportable Legal Entities
Assets
Real estate investments, net of accumulated depreciation	306	317
Loans receivable and other investments, net	(533)	(560)
Investment in unconsolidated joint venture	0	0
Cash and cash equivalents	14,770	40,835
Restricted cash	0	0
Assets held for sale, net	0
Lease intangible assets, net	0	0
Accounts receivable, prepaid expenses and other assets, net	5,171	798
Intercompany	1,893,948	1,972,059
Investment in subsidiaries	1,155,457	1,258,715
Total assets	3,069,119	3,272,164
Liabilities
Secured debt, net	0	0
Revolving credit facility	0	0
Term loans, net	0	0
Senior unsecured notes, net	0	0
Accounts payable and accrued liabilities	22,650	21,750
Lease intangible liabilities, net	0	0
Intercompany	0	0
Total liabilities	22,650	21,750
Total Sabra Health Care REIT, Inc. stockholders’ equity	3,046,469	3,250,414
Noncontrolling interests	0	0
Total equity	3,046,469	3,250,414
Total liabilities and equity	3,069,119	3,272,164
Operating Partnership | Reportable Legal Entities
Assets
Real estate investments, net of accumulated depreciation	0	0
Loans receivable and other investments, net	0	0
Investment in unconsolidated joint venture	0	0
Cash and cash equivalents	0	0
Restricted cash	0	0
Assets held for sale, net	0
Lease intangible assets, net	0	0
Accounts receivable, prepaid expenses and other assets, net	27,962	37,075
Intercompany	2,619,046	2,646,669
Investment in subsidiaries	1,558,253	1,629,795
Total assets	4,205,261	4,313,539
Liabilities
Secured debt, net	0	0
Revolving credit facility	620,000	624,000
Term loans, net	1,094,639	1,094,177
Senior unsecured notes, net	1,307,658	1,307,394
Accounts payable and accrued liabilities	27,507	29,253
Lease intangible liabilities, net	0	0
Intercompany	0	0
Total liabilities	3,049,804	3,054,824
Total Sabra Health Care REIT, Inc. stockholders’ equity	1,155,457	1,258,715
Noncontrolling interests	0	0
Total equity	1,155,457	1,258,715
Total liabilities and equity	4,205,261	4,313,539
Sabra Capital Corporation | Reportable Legal Entities
Assets
Real estate investments, net of accumulated depreciation	0	0
Loans receivable and other investments, net	0	0
Investment in unconsolidated joint venture	0	0
Cash and cash equivalents	0	0
Restricted cash	0	0
Assets held for sale, net	0
Lease intangible assets, net	0	0
Accounts receivable, prepaid expenses and other assets, net	0	0
Intercompany	0	0
Investment in subsidiaries	0	0
Total assets	0	0
Liabilities
Secured debt, net	0	0
Revolving credit facility	0	0
Term loans, net	0	0
Senior unsecured notes, net	0	0
Accounts payable and accrued liabilities	0	0
Lease intangible liabilities, net	0	0
Intercompany	0	0
Total liabilities	0	0
Total Sabra Health Care REIT, Inc. stockholders’ equity	0	0
Noncontrolling interests	0	0
Total equity	0	0
Total liabilities and equity	0	0
Combined Guarantor Subsidiaries | Reportable Legal Entities
Assets
Real estate investments, net of accumulated depreciation	1,597,664	1,609,861
Loans receivable and other investments, net	49,730	50,534
Investment in unconsolidated joint venture	0	0
Cash and cash equivalents	1,570	3,508
Restricted cash	1,845	1,820
Assets held for sale, net	0
Lease intangible assets, net	15,469	15,892
Accounts receivable, prepaid expenses and other assets, net	30,770	58,710
Intercompany	0	0
Investment in subsidiaries	32,540	33,083
Total assets	1,729,588	1,773,408
Liabilities
Secured debt, net	0	0
Revolving credit facility	0	0
Term loans, net	92,745	90,753
Senior unsecured notes, net	0	0
Accounts payable and accrued liabilities	3,344	2,695
Lease intangible liabilities, net	0	0
Intercompany	350,674	399,912
Total liabilities	446,763	493,360
Total Sabra Health Care REIT, Inc. stockholders’ equity	1,282,825	1,280,048
Noncontrolling interests	0	0
Total equity	1,282,825	1,280,048
Total liabilities and equity	1,729,588	1,773,408
Combined Non-Guarantor Subsidiaries | Reportable Legal Entities
Assets
Real estate investments, net of accumulated depreciation	3,839,384	4,243,367
Loans receivable and other investments, net	60,017	63,748
Investment in unconsolidated joint venture	335,701	340,120
Cash and cash equivalents	6,533	5,887
Restricted cash	7,921	7,608
Assets held for sale, net	270,780
Lease intangible assets, net	104,198	115,205
Accounts receivable, prepaid expenses and other assets, net	92,782	81,597
Intercompany	0	0
Investment in subsidiaries	0	0
Total assets	4,717,316	4,857,532
Liabilities
Secured debt, net	115,188	115,679
Revolving credit facility	0	0
Term loans, net	0	0
Senior unsecured notes, net	0	0
Accounts payable and accrued liabilities	48,203	52,148
Lease intangible liabilities, net	79,328	83,726
Intercompany	4,162,320	4,218,816
Total liabilities	4,405,039	4,470,369
Total Sabra Health Care REIT, Inc. stockholders’ equity	307,968	382,830
Noncontrolling interests	4,309	4,333
Total equity	312,277	387,163
Total liabilities and equity	$ 4,717,316	$ 4,857,532

SUMMARIZED CONDENSED CONSOLID_4

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION - Condensed Consolidating Statement of Income (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenues:
Rental and related revenues	$ 116,387	$ 144,255
Interest and other income	3,325	4,338
Resident fees and services	17,061	17,493
Total revenues	136,773	166,086
Expenses:
Depreciation and amortization	44,949	48,005
Interest	36,318	35,818
General and administrative	8,178	7,867
Merger and acquisition costs	6	330
(Recovery of) provision for doubtful accounts, straight-line rental income and loan losses	1,207	1,213
Impairment of real estate	103,134	532
Total expenses	211,121	105,889
Other (expense) income:
Other income (expense)	171	2,820
Net loss on sales of real estate	(1,520)	(472)
Total other (expense) income	(1,349)	2,348
Income in subsidiary	0	0
(Loss) income before (loss) income from unconsolidated joint venture and income tax expense	(75,697)	62,545
(Loss) income from unconsolidated joint venture	(1,383)	446
Income tax expense	(612)	(510)
Net (loss) income	(77,692)	62,481
Net income attributable to noncontrolling interests	(12)	(10)
Net (loss) income attributable to Sabra Health Care REIT, Inc.	(77,704)	62,471
Preferred stock dividends	0	(2,561)
Net (loss) income attributable to common stockholders	$ (77,704)	$ 59,910
Net (loss) income attributable to common stockholders, per:
Basic common share (in dollars per share)	$ (0.44)	$ 0.34
Diluted common share (in dollars per share)	$ (0.44)	$ 0.34
Weighted-average number of common shares outstanding, basic (in shares)	178,385,984	178,294,605
Weighted-average number of common shares outstanding, diluted (in shares)	178,385,984	178,516,388
Triple-Net Portfolio
Expenses:
Operating expenses	$ 5,289	$ 0
Senior Housing - Managed
Expenses:
Operating expenses	12,040	12,124
Elimination
Revenues:
Rental and related revenues	(4,376)	(4,233)
Interest and other income	(96)	(112)
Resident fees and services	0	0
Total revenues	(4,472)	(4,345)
Expenses:
Depreciation and amortization	0	0
Interest	(96)	(112)
General and administrative	0	0
Merger and acquisition costs	0	0
(Recovery of) provision for doubtful accounts, straight-line rental income and loan losses	0	0
Impairment of real estate	0	0
Total expenses	(4,472)	(4,345)
Other (expense) income:
Other income (expense)	0	0
Net loss on sales of real estate	0	0
Total other (expense) income	0	0
Income in subsidiary	103,177	(172,807)
(Loss) income before (loss) income from unconsolidated joint venture and income tax expense	103,177	(172,807)
(Loss) income from unconsolidated joint venture	0	0
Income tax expense	0	0
Net (loss) income	103,177	(172,807)
Net income attributable to noncontrolling interests	0	0
Net (loss) income attributable to Sabra Health Care REIT, Inc.		(172,807)
Preferred stock dividends		0
Net (loss) income attributable to common stockholders	103,177	(172,807)
Elimination | Triple-Net Portfolio
Expenses:
Operating expenses	0
Elimination | Senior Housing - Managed
Expenses:
Operating expenses	(4,376)	(4,233)
Parent Company | Reportable Legal Entities
Revenues:
Rental and related revenues	0	0
Interest and other income	29	10
Resident fees and services	0	0
Total revenues	29	10
Expenses:
Depreciation and amortization	12	222
Interest	0	0
General and administrative	7,525	5,822
Merger and acquisition costs	6	336
(Recovery of) provision for doubtful accounts, straight-line rental income and loan losses	(27)	2,181
Impairment of real estate	0	0
Total expenses	7,516	8,561
Other (expense) income:
Other income (expense)	0	1,977
Net loss on sales of real estate	0	0
Total other (expense) income	0	1,977
Income in subsidiary	(69,777)	69,343
(Loss) income before (loss) income from unconsolidated joint venture and income tax expense	(77,264)	62,769
(Loss) income from unconsolidated joint venture	0	0
Income tax expense	(440)	(298)
Net (loss) income	(77,704)	62,471
Net income attributable to noncontrolling interests	0	0
Net (loss) income attributable to Sabra Health Care REIT, Inc.		62,471
Preferred stock dividends		(2,561)
Net (loss) income attributable to common stockholders	(77,704)	59,910
Parent Company | Reportable Legal Entities | Triple-Net Portfolio
Expenses:
Operating expenses	0
Parent Company | Reportable Legal Entities | Senior Housing - Managed
Expenses:
Operating expenses	0	0
Operating Partnership | Reportable Legal Entities
Revenues:
Rental and related revenues	0	0
Interest and other income	96	112
Resident fees and services	0	0
Total revenues	96	112
Expenses:
Depreciation and amortization	0	0
Interest	34,275	32,566
General and administrative	31	14
Merger and acquisition costs	0	0
(Recovery of) provision for doubtful accounts, straight-line rental income and loan losses	0	0
Impairment of real estate	0	0
Total expenses	34,306	32,580
Other (expense) income:
Other income (expense)	(498)	201
Net loss on sales of real estate	0	0
Total other (expense) income	(498)	201
Income in subsidiary	(35,068)	101,610
(Loss) income before (loss) income from unconsolidated joint venture and income tax expense	(69,776)	69,343
(Loss) income from unconsolidated joint venture	0	0
Income tax expense	(1)	0
Net (loss) income	(69,777)	69,343
Net income attributable to noncontrolling interests	0	0
Net (loss) income attributable to Sabra Health Care REIT, Inc.		69,343
Preferred stock dividends		0
Net (loss) income attributable to common stockholders	(69,777)	69,343
Operating Partnership | Reportable Legal Entities | Triple-Net Portfolio
Expenses:
Operating expenses	0
Operating Partnership | Reportable Legal Entities | Senior Housing - Managed
Expenses:
Operating expenses	0	0
Sabra Capital Corporation | Reportable Legal Entities
Revenues:
Rental and related revenues	0	0
Interest and other income	0	0
Resident fees and services	0	0
Total revenues	0	0
Expenses:
Depreciation and amortization	0	0
Interest	0	0
General and administrative	0	0
Merger and acquisition costs	0	0
(Recovery of) provision for doubtful accounts, straight-line rental income and loan losses	0	0
Impairment of real estate	0	0
Total expenses	0	0
Other (expense) income:
Other income (expense)	0	0
Net loss on sales of real estate	0	0
Total other (expense) income	0	0
Income in subsidiary	0	0
(Loss) income before (loss) income from unconsolidated joint venture and income tax expense	0	0
(Loss) income from unconsolidated joint venture	0	0
Income tax expense	0	0
Net (loss) income	0	0
Net income attributable to noncontrolling interests	0	0
Net (loss) income attributable to Sabra Health Care REIT, Inc.		0
Preferred stock dividends		0
Net (loss) income attributable to common stockholders	0	0
Sabra Capital Corporation | Reportable Legal Entities | Triple-Net Portfolio
Expenses:
Operating expenses	0
Sabra Capital Corporation | Reportable Legal Entities | Senior Housing - Managed
Expenses:
Operating expenses	0	0
Combined Guarantor Subsidiaries | Reportable Legal Entities
Revenues:
Rental and related revenues	32,125	45,464
Interest and other income	1,231	1,267
Resident fees and services	0	0
Total revenues	33,356	46,731
Expenses:
Depreciation and amortization	12,888	14,930
Interest	903	790
General and administrative	167	431
Merger and acquisition costs	0	0
(Recovery of) provision for doubtful accounts, straight-line rental income and loan losses	0	(971)
Impairment of real estate	0	532
Total expenses	14,972	15,712
Other (expense) income:
Other income (expense)	492	410
Net loss on sales of real estate	(375)	(56)
Total other (expense) income	117	354
Income in subsidiary	1,668	1,854
(Loss) income before (loss) income from unconsolidated joint venture and income tax expense	20,169	33,227
(Loss) income from unconsolidated joint venture	0	0
Income tax expense	(105)	(53)
Net (loss) income	20,064	33,174
Net income attributable to noncontrolling interests	0	0
Net (loss) income attributable to Sabra Health Care REIT, Inc.		33,174
Preferred stock dividends		0
Net (loss) income attributable to common stockholders	20,064	33,174
Combined Guarantor Subsidiaries | Reportable Legal Entities | Triple-Net Portfolio
Expenses:
Operating expenses	1,014
Combined Guarantor Subsidiaries | Reportable Legal Entities | Senior Housing - Managed
Expenses:
Operating expenses	0	0
Combined Non-Guarantor Subsidiaries | Reportable Legal Entities
Revenues:
Rental and related revenues	88,638	103,024
Interest and other income	2,065	3,061
Resident fees and services	17,061	17,493
Total revenues	107,764	123,578
Expenses:
Depreciation and amortization	32,049	32,853
Interest	1,236	2,574
General and administrative	455	1,600
Merger and acquisition costs	0	(6)
(Recovery of) provision for doubtful accounts, straight-line rental income and loan losses	1,234	3
Impairment of real estate	103,134	0
Total expenses	158,799	53,381
Other (expense) income:
Other income (expense)	177	232
Net loss on sales of real estate	(1,145)	(416)
Total other (expense) income	(968)	(184)
Income in subsidiary	0	0
(Loss) income before (loss) income from unconsolidated joint venture and income tax expense	(52,003)	70,013
(Loss) income from unconsolidated joint venture	(1,383)	446
Income tax expense	(66)	(159)
Net (loss) income	(53,452)	70,300
Net income attributable to noncontrolling interests	(12)	(10)
Net (loss) income attributable to Sabra Health Care REIT, Inc.		70,290
Preferred stock dividends		0
Net (loss) income attributable to common stockholders	(53,464)	70,290
Combined Non-Guarantor Subsidiaries | Reportable Legal Entities | Triple-Net Portfolio
Expenses:
Operating expenses	4,275
Combined Non-Guarantor Subsidiaries | Reportable Legal Entities | Senior Housing - Managed
Expenses:
Operating expenses	$ 16,416	$ 16,357

SUMMARIZED CONDENSED CONSOLID_5

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION - Condensed Consolidating Statement of Comprehensive (Loss) Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Condensed Financial Statements, Captions [Line Items]
Net (loss) income	$ (77,692)	$ 62,481
Unrealized gain (loss), net of tax:
Foreign currency translation loss	(560)	(374)
Unrealized (loss) gain on cash flow hedges	(13,488)	9,898
Total other comprehensive (loss) income	(14,048)	9,524
Comprehensive (loss) income	(91,740)	72,005
Comprehensive income attributable to noncontrolling interest	(12)	(10)
Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc.	(91,752)	71,995
Elimination
Condensed Financial Statements, Captions [Line Items]
Net (loss) income	103,177	(172,807)
Unrealized gain (loss), net of tax:
Foreign currency translation loss	0	0
Unrealized (loss) gain on cash flow hedges	0	0
Total other comprehensive (loss) income	0	0
Comprehensive (loss) income	103,177	(172,807)
Comprehensive income attributable to noncontrolling interest	0	0
Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc.	103,177	(172,807)
Parent Company | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net (loss) income	(77,704)	62,471
Unrealized gain (loss), net of tax:
Foreign currency translation loss	0	0
Unrealized (loss) gain on cash flow hedges	0	0
Total other comprehensive (loss) income	0	0
Comprehensive (loss) income	(77,704)	62,471
Comprehensive income attributable to noncontrolling interest	0	0
Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc.	(77,704)	62,471
Operating Partnership | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net (loss) income	(69,777)	69,343
Unrealized gain (loss), net of tax:
Foreign currency translation loss	(1,437)	841
Unrealized (loss) gain on cash flow hedges	(13,486)	9,903
Total other comprehensive (loss) income	(14,923)	10,744
Comprehensive (loss) income	(84,700)	80,087
Comprehensive income attributable to noncontrolling interest	0	0
Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc.	(84,700)	80,087
Sabra Capital Corporation | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net (loss) income	0	0
Unrealized gain (loss), net of tax:
Foreign currency translation loss	0	0
Unrealized (loss) gain on cash flow hedges	0	0
Total other comprehensive (loss) income	0	0
Comprehensive (loss) income	0	0
Comprehensive income attributable to noncontrolling interest	0	0
Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc.	0	0
Combined Guarantor Subsidiaries | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net (loss) income	20,064	33,174
Unrealized gain (loss), net of tax:
Foreign currency translation loss	678	(928)
Unrealized (loss) gain on cash flow hedges	(2)	(5)
Total other comprehensive (loss) income	676	(933)
Comprehensive (loss) income	20,740	32,241
Comprehensive income attributable to noncontrolling interest	0	0
Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc.	20,740	32,241
Combined Non-Guarantor Subsidiaries | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net (loss) income	(53,452)	70,300
Unrealized gain (loss), net of tax:
Foreign currency translation loss	199	(287)
Unrealized (loss) gain on cash flow hedges	0	0
Total other comprehensive (loss) income	199	(287)
Comprehensive (loss) income	(53,253)	70,013
Comprehensive income attributable to noncontrolling interest	(12)	(10)
Comprehensive (loss) income attributable to Sabra Health Care REIT, Inc.	$ (53,265)	$ 70,003

SUMMARIZED CONDENSED CONSOLID_6

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION - Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	$ 53,959	$ 101,647
Cash flows from investing activities:
Acquisition of real estate	0	(172,001)
Origination and fundings of loans receivable	(2,776)	(13,232)
Origination and fundings of preferred equity investments	0	(928)
Additions to real estate	(5,072)	(11,539)
Repayments of loans receivable	5,251	28,805
Repayments of preferred equity investments	2,087	234
Investment in unconsolidated joint venture	0	(354,461)
Net proceeds from the sales of real estate	6,857	6,743
Distribution from subsidiaries	0	0
Intercompany financing	0	0
Net cash provided by (used in) investing activities	6,347	(516,379)
Cash flows from financing activities:
Net repayments of revolving credit facility	(4,000)	(30,000)
Principal payments on secured debt	(849)	(1,061)
Payments of deferred financing costs	(6)	(6)
Distributions to noncontrolling interests	(36)	(37)
Issuance of common stock, net	(2,323)	(499)
Dividends paid on common and preferred stock	(80,260)	(82,789)
Distribution to parent	0	0
Intercompany financing	0	0
Net cash used in financing activities	(87,474)	(114,392)
Net decrease in cash, cash equivalents and restricted cash	(27,168)	(529,124)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	149	(155)
Cash, cash equivalents and restricted cash, beginning of period	59,658	587,449
Cash, cash equivalents and restricted cash, end of period	32,639	58,170
Elimination
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	0	0
Cash flows from investing activities:
Acquisition of real estate		0
Origination and fundings of loans receivable	0	0
Origination and fundings of preferred equity investments		0
Additions to real estate	0	0
Repayments of loans receivable	0	0
Repayments of preferred equity investments	0	0
Investment in unconsolidated joint venture		0
Net proceeds from the sales of real estate	0	0
Distribution from subsidiaries	(5,138)	(5,114)
Intercompany financing	(12,238)	947,430
Net cash provided by (used in) investing activities	(17,376)	942,316
Cash flows from financing activities:
Net repayments of revolving credit facility	0	0
Principal payments on secured debt	0	0
Payments of deferred financing costs	0	0
Distributions to noncontrolling interests	0	0
Issuance of common stock, net	0	0
Dividends paid on common and preferred stock	0	0
Distribution to parent	5,138	5,114
Intercompany financing	12,238	(947,430)
Net cash used in financing activities	17,376	(942,316)
Net decrease in cash, cash equivalents and restricted cash	0	0
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0
Cash, cash equivalents and restricted cash, beginning of period	0	0
Cash, cash equivalents and restricted cash, end of period	0	0
Parent Company | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	49,833	97,936
Cash flows from investing activities:
Acquisition of real estate		0
Origination and fundings of loans receivable	0	0
Origination and fundings of preferred equity investments		0
Additions to real estate	0	(38)
Repayments of loans receivable	0	0
Repayments of preferred equity investments	0	0
Investment in unconsolidated joint venture		0
Net proceeds from the sales of real estate	0	0
Distribution from subsidiaries	2,569	2,557
Intercompany financing	4,116	(488,718)
Net cash provided by (used in) investing activities	6,685	(486,199)
Cash flows from financing activities:
Net repayments of revolving credit facility	0	0
Principal payments on secured debt	0	0
Payments of deferred financing costs	0	0
Distributions to noncontrolling interests	0	0
Issuance of common stock, net	(2,323)	(499)
Dividends paid on common and preferred stock	(80,260)	(82,789)
Distribution to parent	0	0
Intercompany financing	0	0
Net cash used in financing activities	(82,583)	(83,288)
Net decrease in cash, cash equivalents and restricted cash	(26,065)	(471,551)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0
Cash, cash equivalents and restricted cash, beginning of period	40,835	511,670
Cash, cash equivalents and restricted cash, end of period	14,770	40,119
Operating Partnership | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	0	0
Cash flows from investing activities:
Acquisition of real estate		0
Origination and fundings of loans receivable	0	0
Origination and fundings of preferred equity investments		0
Additions to real estate	0	0
Repayments of loans receivable	0	0
Repayments of preferred equity investments	0	0
Investment in unconsolidated joint venture		0
Net proceeds from the sales of real estate	0	0
Distribution from subsidiaries	2,569	2,557
Intercompany financing	8,122	(458,712)
Net cash provided by (used in) investing activities	10,691	(456,155)
Cash flows from financing activities:
Net repayments of revolving credit facility	(4,000)	(30,000)
Principal payments on secured debt	0	0
Payments of deferred financing costs	(6)	(6)
Distributions to noncontrolling interests	0	0
Issuance of common stock, net	0	0
Dividends paid on common and preferred stock	0	0
Distribution to parent	(2,569)	(2,557)
Intercompany financing	(4,116)	488,718
Net cash used in financing activities	(10,691)	456,155
Net decrease in cash, cash equivalents and restricted cash	0	0
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0
Cash, cash equivalents and restricted cash, beginning of period	0	0
Cash, cash equivalents and restricted cash, end of period	0	0
Sabra Capital Corporation | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	0	0
Cash flows from investing activities:
Acquisition of real estate		0
Origination and fundings of loans receivable	0	0
Origination and fundings of preferred equity investments		0
Additions to real estate	0	0
Repayments of loans receivable	0	0
Repayments of preferred equity investments	0	0
Investment in unconsolidated joint venture		0
Net proceeds from the sales of real estate	0	0
Distribution from subsidiaries	0	0
Intercompany financing	0	0
Net cash provided by (used in) investing activities	0	0
Cash flows from financing activities:
Net repayments of revolving credit facility	0	0
Principal payments on secured debt	0	0
Payments of deferred financing costs	0	0
Distributions to noncontrolling interests	0	0
Issuance of common stock, net	0	0
Dividends paid on common and preferred stock	0	0
Distribution to parent	0	0
Intercompany financing	0	0
Net cash used in financing activities	0	0
Net decrease in cash, cash equivalents and restricted cash	0	0
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0
Cash, cash equivalents and restricted cash, beginning of period	0	0
Cash, cash equivalents and restricted cash, end of period	0	0
Combined Guarantor Subsidiaries | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	(379)	(55)
Cash flows from investing activities:
Acquisition of real estate		(172,001)
Origination and fundings of loans receivable	(352)	(1,027)
Origination and fundings of preferred equity investments		(928)
Additions to real estate	(1,936)	(3,496)
Repayments of loans receivable	61	7,491
Repayments of preferred equity investments	2,087	234
Investment in unconsolidated joint venture		0
Net proceeds from the sales of real estate	3,829	0
Distribution from subsidiaries	0	0
Intercompany financing	0	0
Net cash provided by (used in) investing activities	3,689	(169,727)
Cash flows from financing activities:
Net repayments of revolving credit facility	0	0
Principal payments on secured debt	0	0
Payments of deferred financing costs	0	0
Distributions to noncontrolling interests	0	0
Issuance of common stock, net	0	0
Dividends paid on common and preferred stock	0	0
Distribution to parent	0	0
Intercompany financing	(5,331)	134,797
Net cash used in financing activities	(5,331)	134,797
Net decrease in cash, cash equivalents and restricted cash	(2,021)	(34,985)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	108	(72)
Cash, cash equivalents and restricted cash, beginning of period	5,328	37,359
Cash, cash equivalents and restricted cash, end of period	3,415	2,302
Combined Non-Guarantor Subsidiaries | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	4,505	3,766
Cash flows from investing activities:
Acquisition of real estate		0
Origination and fundings of loans receivable	(2,424)	(12,205)
Origination and fundings of preferred equity investments		0
Additions to real estate	(3,136)	(8,005)
Repayments of loans receivable	5,190	21,314
Repayments of preferred equity investments	0	0
Investment in unconsolidated joint venture		(354,461)
Net proceeds from the sales of real estate	3,028	6,743
Distribution from subsidiaries	0	0
Intercompany financing	0	0
Net cash provided by (used in) investing activities	2,658	(346,614)
Cash flows from financing activities:
Net repayments of revolving credit facility	0	0
Principal payments on secured debt	(849)	(1,061)
Payments of deferred financing costs	0	0
Distributions to noncontrolling interests	(36)	(37)
Issuance of common stock, net	0	0
Dividends paid on common and preferred stock	0	0
Distribution to parent	(2,569)	(2,557)
Intercompany financing	(2,791)	323,915
Net cash used in financing activities	(6,245)	320,260
Net decrease in cash, cash equivalents and restricted cash	918	(22,588)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	41	(83)
Cash, cash equivalents and restricted cash, beginning of period	13,495	38,420
Cash, cash equivalents and restricted cash, end of period	$ 14,454	$ 15,749

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - $ / shares	May 08, 2019	Feb. 05, 2019	Mar. 31, 2019	Mar. 31, 2018
Subsequent Event [Line Items]
Quarterly cash dividend declared on common stock (in dollars per share)		$ 0.45	$ 0.45	$ 0.45
Subsequent Event
Subsequent Event [Line Items]
Quarterly cash dividend declared on common stock (in dollars per share)	$ 0.45

Uncategorized Items - sbra-2019

Label	Element	Value
Accounting Standards Update 2017-12 [Member] | Accumulated Distributions in Excess of Net Income [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (795,000)
Accounting Standards Update 2017-12 [Member] | AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	795,000
Accounting Standards Update 2016-02 [Member] | Accumulated Distributions in Excess of Net Income [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	(32,502,000)
Accounting Standards Update 2016-02 [Member] | Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (32,502,000)